Vitamin D and Skeletal Muscle Function in Chronic Obstructive Pulmonary Disease: Clinical Associations, Molecular Mechanisms and Genetic Influences by Jackson, Abigail
Vitamin D and Skeletal Muscle 
Function in Chronic Obstructive 
Pulmonary Disease: Clinical 
Associations, Molecular Mechanisms 
and Genetic Influences 
 
Submitted by Dr Abigail Jackson for the 
degree of MD(Res) 
 
The Respiratory Muscle Laboratory 
Royal Brompton Hospital / National Heart 
and Lung Institute 
Imperial College, University of London 
 2 
The copyright of this thesis rests with the author and is made available under a 
Creative Commons Attribution Non-Commercial No Derivatives licence. Researchers 
are free to copy, distribute or transmit the thesis on the condition that they attribute it, 
that they do not use it for commercial purposes and that they do not alter, transform or 
build upon it. For any reuse or redistribution, researchers must make clear to others 
the licence terms of this work 
The work described in this thesis is my own work unless otherwise referenced in the 
text.  
 
Abstract 
 
This thesis investigates the role that serum 25(OH)D and serum 1,25(OH)2D 
concentration play in skeletal muscle dysfunction in patients with Chronic Obstructive 
Pulmonary Disease (COPD) with reference to clinical impact, potential molecular 
mechanisms and genetic influences. 
 
In a large cohort of COPD patients, neither serum 25(OH)D or serum 1,25()H)2D 
concentration were found to be associated with any volitional or non-volitional 
measures of peripheral or respiratory muscle strength.  In a group of age and sex 
matched healthy control subjects serum 1,25()H)2D concentration was associated with 
muscle strength measures even after correction for potential confounding factors.  
Vitamin D status was not associated with quadriceps endurance in either COPD or 
control subjects when measured by repetitive magnetic stimulation. 
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A sub-set of patients underwent a quadriceps muscle biopsy and mRNA levels of 
muscle fibre type and myogenic regulatory factors were measured.  Serum 25(OH)D 
concentration was associated with MyHCIIa mRNA expression in control, but not 
COPD, subjects.  Myf5 mRNA expression was strongly associated with MHC1 
mRNA expression whilst mrf4 mRNA expression was strongly associated with 
MyHCIIa mRNA expression in control, but not COPD, subjects. 
 
Genotyping for all subjects included in the study was carried out for certain 
polymorphisms that were chosen because they have previously been reported to have 
an influence on the renin-angiotensin system in normal subjects, and may thus have 
an influence on skeletal muscle strength, or were already associated with muscle 
strength.  In combination, the ACE I/D polymorphism, the AGT Met235Thr and the 
ATR1 A1166C polymorphisms had a significant influence on muscle strength in the 
COPD group.  In normal subjects, the ACE I/D polymorphism was significantly 
associated with serum 25(OH)D concentration, and this association was stronger after 
correcting for confounding factors. 
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Abbreviations Used 
 
1,25(OH)2D 1,25 di-hydroxyvitamin D 
25(OH)D 25 hydroxyvitamin D 
ABG Arterial blood gases 
ACE Angiotensin converting enzyme 
ADD Average daily dose 
ATP Adenosine triphosphate 
ATR1 Angiotensin II receptor type I 
ATS American Thoracic Society 
BK2R Bradykinin 2 receptor 
BMD Bone mineral density 
BMI Body mass index 
BTS British Thoracic Society 
COPD Chronic obstructive pulmonary disease 
CRP C-reactive protein 
CYP27B1 1 α-hydroxlase 
D allele Deletion allele of ACE gene polymorphism 
DEXA Dual energy x-ray absorptiometry 
DBP Vitamin D binding protein 
EIA Enzyme immunoassay 
ERK Extracellular signal-regulated kinases 
FEV1 Forced expiratory volume in one second 
FFM Fat free mass 
FFMI Fat free mass index 
FVC Forced vital capacity 
GOLD Global initiative for chronic obstructive lung disease 
hsCRP High sensitivity C reactive protein 
I allele Insertion allele of ACE gene polymorphism 
IFNγ Interferon γ 
IGF-1 etc Insulin like growth factor 
IL1 etc Interleukin 
IP3 Inositol 1,4,5 triphosphate 
MAPK Mitogen activated protein kinase 
MHC I etc. Myosin heavy chain 
MRFs Myogenic regulatory factors 
MuRF-1 Muscle ring finger protein 1 
NHANES National health and nutrition examination survey 
ODN oligodeoxynucleotide 
PaCO2 Arterial carbon dioxide tension 
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PaO2 Arterial oxygen tension 
PCR Polymerase chain reaction 
PI3K phosphatidylinositol-3-kinase 
PPAR Peroxisome proliferator activated receptor 
PTH Parathyroid hormone 
QMVC Quadriceps maximum voluntary contraction 
QOL Quality of life 
qPCR Quantitative polymerase chain reaction 
RAS Renin angiotensin system 
RCT Randomised Controlled Trial 
REE Resting energy expenditure 
RIA Radioimmunoassay 
RV Residual volume 
SD Standard deviation 
SGRQ St George's Respiratory Questionnaire 
SNiP Sniff nasal pressure 
SNP Single nucleotide polymorphism 
TGFβ Transforming growth factor β 
TLC Total lung capacity 
TLCO Carbon monoxide transfer factor 
TNFα  Tumour necrosis factor alpha 
Tregs T regulatory cells 
TRPC3 transient receptor potential cation channel, subfamily C, member 3 
TwQu Twitch quadriceps force 
URTI Upper respiratory tract infection 
US Ultrasound 
VDR Vitamin D receptor 
VDRKO Vitamin D receptor knockout 
VO2 max Maximum oxygen consumption 
WBC White blood cells 
YPAS Yale physical activity survey 
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Chapter 1: Introduction 
 
 
1.1:  Chronic Obstructive Pulmonary Disease 
 
The word emphysema is Greek meaning to inflate, and is derived from the word 
physa meaning breath.  The term was originally used to describe air in the tissues i.e. 
subcutaneous emphysema.  In 1721, Ruysch provided the first description of 
emphysema in the human lung.  However, it was not until the 19
th
 century that further 
light was shed on the disease by the French physician Laennec (Laennec 1834).  He 
recognized that the disease was associated with chronic bronchitis and described 
‘marked variations in the size of the air vesicles, which might be smaller than a millet 
seed or as large as a cherry stone or haricot’.  Emphysema and chronic bronchitis are 
now included under the term Chronic Obstructive Pulmonary Disease (COPD) which 
is defined as a chronic lung disease where there is progressive damage to airways and 
lung parenchyma causing airflow obstruction, usually as a result of inhalation of 
cigarette smoke.  It is estimated that worldwide, 210 million people suffer from 
COPD and it is predicted that it will be the fourth leading cause of death by 2030 
(Bousquet, Dahl et al. 2007). 
 
1.2:  Pathophysiology of COPD 
 
The inhalation of cigarette smoke, potential occupational exposures (Blanc, Eisner et 
al. 2004), and in the developing world the indoor exposure to smoke from biomass 
fuel (Dossing, Khan et al. 1994; Ozbay, Uzun et al. 2001), contribute to the 
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development of parenchymal destruction and narrowing of the airway lumen though 
smooth muscle hypertrophy, airway inflammation and loss of elastic recoil.  The 
resulting loss of alveolar surface area, ventilation perfusion mismatch, airflow 
limitation, and gas trapping all contribute to the dyspnoea and fatigue that patients 
experience.  The severity of disease is classified through the FEV1 which is a measure 
of the degree of airflow limitation; subjects are unable to achieve faster flow rates 
despite maximum efforts. 
 
The pathological mechanisms of COPD are complex and poorly understood.  There is 
evidence for alteration of the protease / antiprotease balance mediated by an increase 
in neutrophils and macrophages (Djekic, Gaggar et al. 2009), increased oxidative 
stress (MacNee 2005), autoimmune dysfunction (Cosio, Saetta et al. 2009) and 
dysregulation of lung development pathways including retinoic acid, notch and 
hedgehog signalling (Shi, Chen et al. 2009).  Although cigarette smoking is the 
predominant cause of COPD, not all of those who smoke develop the disease.  
Genetic influences are therefore likely to play an important role. 
 
Although classified as a disease of the respiratory system, there are a number of 
systemic complications which are well described in COPD, some of which are more 
closely linked to mortality than the degree of impairment in lung function.  These 
include weight loss, loss of muscle mass and muscle weakness, systemic 
inflammation, increased prevalence of osteopenia and osteoporosis and increased 
prevalence of cardiovascular disease and certain types of cancer. 
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1.3:  Weight loss in COPD 
 
Weight loss in relation to COPD was first recognized in 1898 by Fowler and Godlee 
(Fowler 1898).   However, it was not until half a century later that its importance as a 
prognostic factor in COPD was first demonstrated by Boushy et al (Boushy, Adhikari 
et al. 1964).  A few years later, Vandenbergh et al reported a 5 year mortality of 50% 
in patients with weight loss versus 5 year mortality of 20% in those with stable weight 
(Vandenbergh, Van de Woestijne et al. 1967).  More recent studies have confirmed 
this association between weight loss and poor prognosis in COPD.  The Copenhagen 
City Heart Study found that weight loss in all patients (Prescott, Almdal et al. 2002), 
and body mass index (BMI) in patients with an FEV1 less than 50% predicted were 
independent predictors of mortality (Landbo, Prescott et al. 1999).  In the National 
Institutes of Health intermittent positive pressure breathing trial, weight as a 
proportion of ideal body weight was a predictor of mortality independent of FEV1 
(Wilson, Rogers et al. 1989).  An incidence of weight loss of 25% in moderate to 
severe COPD has been reported and 10-15% in mild COPD (Wilson, Rogers et al. 
1989; Schols, Soeters et al. 1993; Engelen, Schols et al. 1994).  It has also been 
shown that patients who gain weight after a program of nutritional support have an 
improved prognosis, whilst those who fail to gain weight have an increased mortality 
(Schols, Slangen et al. 1998). 
 
1.4:  Loss of muscle in COPD 
 
Weight gain or loss may be due to changes in lean body weight (fat free mass) or fat 
mass.  Loss of fat free mass (FFM) has been demonstrated in patients with COPD, 
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more commonly in those who are hypoxaemic or have a reduced gas transfer capacity 
(Schols, Mostert et al. 1991),  Schols et al have described different patterns of body 
composition in COPD (Schols, Soeters et al. 1993).  Whilst some patients have a low 
BMI and a low FFM (cachexia), others have a low FFM whilst maintaining their BMI 
(muscle atrophy).  Both of these groups have decreased exercise capacity and 
increased mortality compared to those with a low BMI who have maintained their 
FFM (semi starvation).   
 
1.5:  Skeletal Muscle Physiology 
 
Skeletal muscle contracts to generate shortening or tension. When a nerve impulse 
reaches the neuromuscular junction, acetylcholine is released from the presynaptic 
membrane, which binds to receptors on the motor end plate causing depolarisation. 
This depolarisation is propagated through the sarcoplasmic reticulum and causes 
intracellular calcium release and activation of the contractile mechanism. 
 
The molecular mechanism of muscle contraction is based on the sliding filament 
model proposed by Huxley in 1971 (Huxley and Simmons 1971). Each muscle fibre is 
made up of hundreds or thousands of myofibrils, which form the contractile 
mechanism. Myofibrils are themselves composed of long strands of smaller units, 
sarcomeres, which are made up of two types of contractile protein filaments, actin and 
myosin. Actin fibres make up the thin filament and are anchored to the Z line, a sheet 
of -actinin, which also connects adjacent myofibrils. Actin filaments are associated 
with another protein, tropomysin that regulates binding to myosin itself in a complex 
with three troponin subunits (Troponin I, C and T). Between and parallel to the actin 
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filaments are myosin filaments. Myosin is composed of two identical ‘heavy’ chains 
arranged in an -helix and two additional light chains forming a globular head that 
has enzymatic activity and can interact with the actin filament.  
 
At rest the tropomysin blocks the binding of the myosin head to the actin filament. 
Above a critical level of intracellular calcium there is a conformational change in the 
troponin subunits, which causes the tropomysin complex to move exposing the 
binding site for the myosin heads. This binding produces cross bridges which undergo 
conformational change to work in a manner analogous to the oars of a boat. The 
formation of cross bridges is energy dependent, requiring hydrolysis of ATP to ADP 
and inorganic phosphate. 
 
1.6:  Muscle fibre type 
 
Adult mammalian skeletal muscle is composed of four myosin heavy chain isoforms, 
with varying parameters of chemomechanical transduction mediated through their 
ATP hydrolysis rate and shortening velocity. These isoforms determine fibre type 
which can be Type I, IIa, IIb and IIx (Schiaffino and Reggiani 1996). Type I fibres 
have a slower twitch and develop relatively less tension but have relative fatigue 
resistance because of their aerobic metabolism. By contrast type IIb/x fibres have a 
fast high-tension twitch but are fatigable because of their anaerobic/gycolytic 
metabolism. Type IIa fibres have intermediate properties (Harridge, Bottinelli et al. 
1996). In humans it is likely that only IIx and not IIb isoforms are expressed (Pereira, 
Andrikopoulos et al. 1997; Pereira Sant'Ana, Ennion et al. 1997) and the MHC IIb 
gene has not been found to be expressed in human muscle fibres (Bottinelli and 
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Reggiani 2000) 
 
1.7:  Muscle function in COPD 
 
Skeletal muscle strength is defined as ‘the capacity of the muscle to develop maximal 
force’, whilst skeletal muscle endurance is defined as ‘the capacity of the muscle to 
maintain a certain force and to resist fatigue’.  If skeletal muscle depletion is an 
important factor in COPD, it is logical to conclude that skeletal muscle function may 
also be affected; FFM has been shown to correlate strongly with peripheral and 
respiratory muscle strength in COPD (Engelen, Schols et al. 1994; Engelen, Schols et 
al. 2000).   
 
Work has focused on the quadriceps muscle as it is one of the main muscles of 
locomotion, is easily accessible and it is possible to carry out supramaximal nerve 
stimulation to obtain non-volitional measures of strength. This is important because 
the presence of  both quadriceps and adductor pollicis weakness have been suggested 
in COPD using volitional techniques (Bernard, LeBlanc et al. 1998) whereas when 
measured using magnetic nerve stimulation, only quadriceps weakness has been 
confirmed (Man, Soliman et al. 2003).  The incidence of quadriceps weakness in 
moderate to severe COPD is 30% (Swallow, Reyes et al. 2007) and when compared 
with healthy age matched controls, the mean reduction in quadriceps strength is 
approximately 30% (Man, Soliman et al. 2003).  Quadriceps weakness has been 
shown to be related to impaired quality of life (Simpson, Killian et al. 1992), exercise 
limitation (Gosselink, Troosters et al. 1996) and increased health care utilization 
(Decramer, Gosselink et al. 1997), as well as being a more powerful prognostic 
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indicator than FFM or forced expiratory volume in one second (FEV1) (Swallow, 
Reyes et al. 2007) (figure 1.1). A reduction in quadriceps endurance has also been 
demonstrated in COPD (Coronell, Orozco-Levi et al. 2004; Swallow, Gosker et al. 
2007).    
 
Figure 1.1:  Mortality in COPD subjects with demonstrated quadriceps 
weakness (Swallow et al 2007) 
 
Biopsy studies of the quadriceps in COPD have shown reduced capillarity (Jobin, 
Maltais et al. 1998) and oxidative capacity (Jakobsson, Jorfeldt et al. 1990) as well as 
muscle atrophy, with a reduction in fibre cross sectional area. A consistent finding is a 
reduction in the proportion of Type I compared to Type II muscle fibres (Jakobsson, 
Jorfeldt et al. 1990).  There appears to be a decrease in the number of Type I fibres, 
whilst Type IIx fibres have a reduced cross-sectional area consistent with a fibre type 
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shift from type I to type IIx fibres and then a subsequent atrophy of Type IIx fibres 
(Gosker, Kubat et al. 2003).    
 
It is not clear whether loss of muscle strength is due solely to decreased muscle bulk 
or whether a myopathy of the skeletal muscle develops.  During exercise, there is 
early lactate production in patients with COPD despite similar oxygen delivery 
(Maltais, Jobin et al. 1998) as well as reduced overall mechanical efficiency 
(Richardson, Leek et al. 2004) consistent with intrinsic muscular abnormalities.  On 
the other hand, force per unit cross-sectional area is maintained.  Bernard et al found 
that strength normalised for muscle cross sectional area for patients with COPD was 
the same as in control subjects (Bernard, LeBlanc et al. 1998), and Engelen et al also 
found that strength per kilogram of muscle in COPD patients was similar to controls 
(Engelen, Schols et al. 2000).  These findings support the hypothesis that skeletal 
muscle weakness in COPD can be predominantly explained by a reduction in muscle 
bulk rather a reduction in specific force due to a myopathic process.  
 
At a molecular level, there are mechanisms for atrophy and hypertrophy which are not 
completely understood (figure 1.2).  During conditions of muscle atrophy, there is 
induction of genes for protein degradation (known as atrogenes), whilst expression of 
genes related to growth is suppressed.  Atrophy involves activation of the ubiquitin–
proteasome system which causes breakdown of muscle proteins.  Early on in this 
pathway there is induction of ubiquitin ligases such as atrogin-I and MuRF-I, and it is 
regulated by a family of transcription factors known as FOXO’s (Sandri, Lin et al. 
2006).  Muscle hypertrophy on the other hand has a signalling pathway which 
involves IGF-I, insulin, posphatidylinositol-3 kinase (PI3K) and Akt (Sandri, Lin et 
 26 
al. 2006).  Importantly, Akt has been shown to have an inhibitory effect on FOXO 
transcription factors (Sandri, Sandri et al. 2004).  Transcription factors involved in the 
hypertrophy pathway include the peroxisome proliferator activated receptor (PPAR) 
which has been shown to cause an increase in the proportion of type I fibres in mice 
(Yong-Xu Wang 2004), and it is possible that a deficiency of PPAR or its associated 
cofactors may be relevant to the increase in proportion of Type II fibres seen in 
COPD.  These hypertrophy / atrophy pathways are a final common pathway in all 
mechanisms of skeletal muscle loss.  
 
 
Figure 1.2:  Atrophy / Hypertrophy signalling pathways in skeletal muscle 
 
1.8:  Potential mechanisms of muscle weakness in COPD 
 
A number of different potential mechanisms for loss of body mass and muscle 
strength in COPD have been proposed which include aging, deconditioning, systemic 
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inflammation, oxidative stress, increased resting energy expenditure, nutrition, 
hypoxia, hypercapnia, hormonal factors, corticosteroid treatment and genetic 
susceptibility (American Thoracic Society/European Respiratory Society 1999) 
(1999; Hopkinson, Nickol et al. 2004).   
 
It is well established that reduction in physical activity can lead to deconditioning 
(Appell 1990) with a loss of muscle mass, reduced oxidative capacity, decreased 
capillarity and mitochondrial density and a reduction in proportion of type I fibres, 
consistent with changes that are seen in the muscles of patients with COPD.  
Interestingly, these changes appear to occur relatively quickly.  In healthy elderly 
people, ten days bed rest produces a 16% fall in quadriceps strength (Kortebein, 
Ferrando et al. 2007).   
 
1.8.1:  Systemic versus local factors 
 
Debate is ongoing as to whether muscle weakness in COPD is a generalised, 
systemically determined phenomenon or one that predominantly is the result of 
disuse.  The ‘compartment theory’ is based on the premise that changes in muscle 
function depend on the demands placed upon the muscle in question (Gea, Orozco-
Levi et al. 2001).  It is argued that patients walk less because of dyspnoea, which 
leads to disuse atrophy and quadriceps weakness.  Upper limb strength is relatively 
well maintained because there is preservation of upper body activity and the shoulder 
girdle muscles are also accessory muscles of respiration.  This theory is supported by 
a number of studies which have shown evidence of quadriceps weakness but not loss 
of handgrip strength in COPD (Gea, Orozco-Levi et al. 2001). Gosselink et al have 
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shown that proximal upper limb weakness as well as quadriceps and respiratory 
muscle weakness does occur in COPD whilst handgrip strength and accessory 
respiratory muscle strength is maintained (Gosselink, Troosters et al. 2000). They 
argue that patients continue to use their hands in generalised day to day activity, but 
avoid raising arms and walking. 
 
A more recent study also confirms that reduced physical activity must play a 
significant role in the development of muscle weakness.  Ultrasound (US) was used to 
measure the rectus femoris cross-sectional area and demonstrated that quadriceps 
wasting occurs early in subjects with COPD and is independently associated with 
physical activity (Shrikrishna, Patel et al. 2012). 
 
1.8.2:  Role of exacerbations 
 
Short term studies have shown that exacerbations of COPD are associated with 
increased inflammatory mediators and acute and partially reversible reductions in 
both quadriceps (Spruit, Gosselink et al. 2003) and handgrip strength (Saudny-
Unterberger, Martin et al. 1997). Since exacerbations are also associated with 
immobility (Pitta, Troosters et al. 2006), negative nitrogen balance (Saudny-
Unterberger, Martin et al. 1997), and the administration of corticosteroids it seems 
reasonable to hypothesize that the development of skeletal muscle depletion over time 
would be associated with exacerbation frequency.  When patients are hospitalised for 
an exacerbation, quadriceps strength falls by a further 5%, and recovery of baseline 
strength is not seen in all patients (Jakobsson, Jorfeldt et al. 1990).  Reduced  FFM is 
associated with exacerbation frequency both in a cross sectional study (Hopkinson, 
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Nickol et al. 2004) and with decline in FFM prospectively (Hopkinson, Tennant et al. 
2007).  
 
1.8.3:  Inflammation 
 
Patients with COPD have evidence of systemic as well as airway inflammation with 
elevation of White blood cell count (WBC), C-reactive protein (CRP), Interleukin 6 
(IL-6), Interleukin 8 (IL-8),  tumour necrosis factor alpha (TNFα) and fibrinogen 
demonstrated in COPD compared to control subjects (Gan, Man et al. 2004).  These 
have been shown to increase with COPD exacerbations (Wedzicha, Seemungal et al. 
2000) and persistently raised systemic markers of inflammation over one year have 
been associated with increased mortality in COPD patients (Agusti, Edwards et al.).  
Interestingly in the latter study, TNFα and IL-8 appear to be markers of smoking 
status, either past or present, rather than COPD itself.  
 
TNFα induces protein loss through activation of the ubiquitin-proteasome pathway.  
Direct application of TNFα reduces single fibre force in vitro (Reid, Lannergren et al. 
2002).  A number of studies have linked TNFα with weight loss and depletion of FFM 
in COPD (Eid, Ionescu et al. 2001) and increased circulating TNFα levels are 
associated with a poor response to nutritional intervention in cachectic patients with 
COPD (Schols, Creutzberg et al. 1999).  However, increased TNFα has not been 
found on muscle biopsy in patients with COPD (Barreiro, Schols et al. 2008).   
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1.8.4:  Ageing 
 
Ageing is associated with a relative decrease in fat free mass and an increase in the 
proportion of fat mass, known as sarcopenia.  There is a reduction in type II fibres 
which can be attenuated to some extent by exercise (Larsson 1978).  There is 
accumulating evidence that COPD may be a disease of accelerated ageing.  This 
includes shortened telomere length in peripheral blood leukocytes (Savale, Chaouat et 
al. 2009) which has been shown to be smoking dose dependent, increased oxidative 
stress in the lungs (Drost, Skwarski et al. 2005) in human clinical studies, and the 
development of accelerated ageing and emphysema in klotho knockout mouse models 
(Funada, Nishimura et al. 2004).  Klotho is an ‘antiageing’ molecule that is a 
regulator of oxidative stress and cell senescence. 
 
1.8.5:  Resting energy expenditure  
 
Nutritional depletion will occur if energy expenditure exceeds energy intake.  Total 
daily expenditure is the sum of resting energy expenditure (REE), diet induced 
thermogenesis and physical activity.  REE was found to be elevated in 25% of a group 
of COPD patients (Creutzberg, Schols et al. 1998).  This may be due to an increase in 
the work of breathing or inflammation.   
 
1.8.6:  Corticosteroid therapy 
 
Myopathy is a well recognised complication of  high doses of corticosteroid (Viires, 
Pavlovic et al. 1990).  It classically affects the proximal muscles and muscle biopsies 
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show atrophy of type IIb fibres.  Although steroid induced myopathy certainly can 
occur in COPD (Decramer, de Bock et al. 1996) interpretation is difficult because of 
confounding by the effects of frequent exacerbations themselves which are the usual 
indications for oral steroid therapy. A two week course of prednisolone had no effect 
on skeletal muscle parameters in stable COPD patients (Hopkinson, Man et al. 2004) 
and cross-sectional studies have not found an association between steroid use and 
muscle depletion in COPD (Schols, Soeters et al. 1993; Hopkinson, Nickol et al. 
2004). 
 
1.8.7:  Genetic susceptibility 
 
Genetic susceptibility to loss of muscle mass and muscle weakness in COPD may 
explain why not all patients are affected equally.  Genetic polymorphisms affecting 
muscle strength in normal subjects have been described for the Angiotensin 
Converting enzyme (ACE) (Pescatello, Kostek et al. 2006), PPARα receptor 
(Ahmetov, Mozhayskaya et al. 2006), Insulin Growth Factor-1 (IGF-1) (Kostek, 
Delmonico et al. 2005) and alpha actinin-3 (ACTN-3) (Clarkson, Devaney et al. 
2005) genes.  The deletion allele of the ACE gene polymorphism is associated with 
greater quadriceps strength in COPD patients independent of FFM (Hopkinson, 
Nickol et al. 2004). Variants in the Vitamin D Receptor (VDR) gene are also 
associated with muscle strength in normal and COPD subjects (Hopkinson, Li et al. 
2008), and variants in the bradykinin receptor gene (BDKR) are associated with 
reduction in FFM (Hopkinson, Eleftheriou et al. 2006).  
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1.8.8:  Nutritional Factors 
 
Malnutrition affects approximately a third of patients with COPD and appears to 
worsen with more severe disease (Vermeeren, Creutzberg et al. 2006).  It has been 
linked to skeletal muscle strength in normal subjects as well as those with COPD 
(Vermeeren, Creutzberg et al. 2006), but supplementation studies have shown 
conflicting results with regard to improvements in peripheral and respiratory muscle 
strength (Weekes, Emery et al. 2009) and patients have difficulty in increasing their 
caloric intake sufficiently due to symptoms of bloating, satiety and dyspnoea 
.   
Three small studies have shown an increase in respiratory muscle strength with 
nutritional supplementation (Efthimiou, Fleming et al. 1988; Whittaker, Ryan et al. 
1990; Rogers, Donahoe et al. 1992).  However, other studies have failed to replicate 
this. A recent Cochrane review has looked at randomised controlled trials giving at 
least two weeks of any caloric supplementation, and found significant improvements 
in anthropometric measures, and exercise capacity in malnourished patients only 
(Ferreira, Brooks et al. 2012).   
 
Creatine is a nutritional supplement which rapidly undergoes reversible 
phosphorylation in skeletal muscle to phosphocreatine and provides a source of high 
energy phosphate.  Creatine supplementation has been found to enhance exercise 
performance in healthy populations (Branch 2003).  One study has looked at creatine 
supplementation in patients with COPD and found that 12 weeks of supplementation 
combined with a rehabilitation programme showed improvements in FFM, quadriceps 
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strength and endurance compared to controls.  However no improvement in exercise 
performance was seen (Fuld, Kilduff et al. 2005). 
 
1.9: Vitamin D 
 
Vitamin D is a pleiotropic micronutrient which has recently been the focus of a lot of 
research in many areas.  It’s well known effects are on bone turnover in its role of 
maintaining serum calcium levels in the body but it has also been recognised to have a 
role in skeletal muscle function in normal subjects.  It also has important roles in the 
immune system, as well as being linked to lung function, and vitamin D insufficiency 
has been associated with osteoporosis and the incidence of some cancers, problems 
which develop in or are associated with COPD.  This makes it an obvious target for 
research in this area. 
 
1.10: Vitamin D metabolism 
 
Cholecalciferol is produced by the action of sunlight on the skin, although it can also 
be included in the diet.  Cholecalciferol is metabolised in the liver to 25 
hydroxyvitamin D (25(OH)D), which is transported and stored in the blood bound to 
vitamin D binding protein (DBP). When required, 25(OH)D is metabolised to the 
active form, 1,25 di-hydroxyvitamin D (1,25(OH)2D), by the enzyme 1α-hydroxlase 
which is produced predominantly in the kidney, although it has now been identified in 
a number of other target organs where 1,25(OH)2D is thought to work in a paracrine 
fashion.  In the kidney, it has been demonstrated that 25(OH)D bound to DBP is 
delivered to the site of the enzyme 1α-hydroxlase by megalin / cubilin mediated 
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receptor endocytosis, although it is not clear whether this process occurs in all tissues 
(Nykjaer, Fyfe et al. 2001).  
 
1,25(OH)2D has a classically recognised role in serum calcium regulation under the 
tight control of parathyroid hormone (PTH) (figure 1.3).  It acts to increase calcium 
absorption from the gut, reduce calcium loss by increasing resorption from the 
kidneys, and to release calcium from available stores ie bone by stimulating 
osteoclasts to resorb calcium. 
 
 
 
Figure 1.3: Actions of serum PTH, 25(OH)D and 1,25(OH)2D in response to low 
serum calcium 
 
Vitamin D deficiency prevents absorbtion of calcium from the gut, and hence ongoing 
resorption of calcium from bone occurs to maintain serum calcium levels leading to 
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osteomalacia in adults, or the development of rickets in childhood (figure 1.4).  
During growth, mineralisation of bone does not occur and subsequent deformity 
develops as the bone does not weight bear effectively. After growth has ceased, 
vitamin D deficiency still causes resorption of bone osteoid and pains and deformity 
can still occur in severe cases.  Rickets became extremely common in Europe and 
particularly England in the mid 20
th
 Century due to the industrialisation process.  
Cities became overcrowded and this in combination with pollution prevented children 
obtaining adequate sunlight exposure.   
 
Figure 1.4:  An example of a family with Ricketts, late 19
th
 Century 
 
It wasn’t until after the First World War that Harriette Chick and Elsie Dalyell 
working in a children’s hospital in Vienna demonstrated that rickets was due to lack 
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of sunlight and could be cured by sunlight exposure, by irradiation from a mercury 
quartz lamp, or by taking cod liver oil which is now known to contain vitamin D3 
(Carpenter 2008). The incidence of rickets in the UK decreased dramatically in the 
1950’s with the introduction of the clean air act, food fortification and increased 
public awareness of the problem.  However, more recently Vitamin D deficiency 
appears to be a re-emerging problem in the UK particularly amongst immigrant 
populations with pigmented skin, lack of sunlight exposure and prolonged periods of 
breast feeding (Prentice). 
 
1.11:  Vitamin D status and skeletal muscle function 
 
Although less well recognised than it classic affects on bone, vitamin D has long been 
known to have an important role in skeletal muscle function.  Patients with 
osteomalacia develop a myopathy which is usually proximal, and skeletal muscle 
biopsies in these patients have shown a reduction in size and number of type II muscle 
fibres (Yoshikawa, Nakamura et al. 1979).    VDR knockout mice have reduced type I 
and type II fibre diameter, and abnormal expression of myogenic regulatory factors 
which is corrected by the addition of 1,25(OH)2D in vitro (Endo, Inoue et al. 2003).   
 
1.12:  Cellular actions of Vitamin D in Skeletal Muscle 
  
1,25(OH)2D exerts its actions by binding to the VDR which has been demonstrated to 
have genomic effects resulting in gene transcription, as well as more rapid non-
genomic effects through VDRs situated in the cytoplasm. The receptors have been 
demonstrated to be identical in chick intestinal cells (Huhtakangas, Olivera et al. 
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2004).  VDRs have been demonstrated in skeletal muscle (Boland, de Boland et al. 
1995) and interestingly the amount of receptors has been shown to decrease with age 
(Bischoff-Ferrari, Borchers et al. 2004).  However there is some controversy over the 
demonstration of VDR in skeletal muscle depending on the technique used.  A more 
recent study using the D6 VDR antibody which does not show any background 
protein in VDR knockout mice, was not able to demonstrate the VDR protein in 
human or rat skeletal muscle (Wang and DeLuca 2011). 
 
There is no doubt however that 1,25(OH)2D has significant actions on skeletal 
muscle. Cell studies have shown that 1,25(OH)2D stimulates initial rapid raised 
intracellular calcium levels through inositol 1,4,5 triphosphate (IP3) mediated release 
of calcium from the sarcoplasmic reticulum (Vazquez, de Boland et al. 2000).  This is 
followed by stimulation of extra-cellular calcium influx through both store operated 
and voltage dependent calcium channels (Bauman, Valinietse et al. 1984; Boland 
1986), an effect which is blocked by the administration of anti-VDR antisense 
oligodeoxynucleotides (ODN’s) and is mediated by TRPC3 protein (Santillan, Katz et 
al. 2004).  This effect has been demonstrated in both immature myoblasts and 
differentiated myotubes (Boland 1986) 
 
Both in vivo and in vitro studies have shown that 25OHD, but not 1,25(OH)2D 
stimulates phosphate uptake in cells which is necessary for adenosine triphosphate 
(ATP) synthesis (de Boland, Albornoz et al. 1983; De Boland, Gallego et al. 1983). 
One study in 25(OH)D and phosphate deficient rats has shown an increase in in vitro 
concentration of phosphate in muscle cells in vitro after the administration of 
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25(OH)D, followed by stimulation of phosphate dependent metabolic processes 
including ATP synthesis (Birge and Haddad 1975) 
 
Other effects of 1,25(OH)2D  demonstrated at a cellular level are those on muscle cell 
growth and differentiation.  Genomic and non-genomic affects have been 
demonstrated in C2C12 myoblast cultures, both of which pathways tend to result in 
cell growth, but the pathways are complex and the role of 1,25(OH)2D not completely 
understood.   
 
1,25(OH)2D has been shown to rapidly activate components of the MAPK family, 
namely MAPK kinase and p38.  The former leads to the activation of ERK1/2 and 
subsequent phosphorylation of a range of proteins and transcription factors involved 
in cell proliferation and differentiation such as c-myc and c-fos, and cAMP response 
element binding protein (Morelli, Buitrago et al. 2001; Ronda, Buitrago et al. 2007).  
p38 has been demonstrated to activate heat shock protein 27 which has an important 
role in its actions on the skeletal muscle cytoskeleton (An, Fabry et al. 2004; 
Buitrago, Ronda et al. 2006) 
 
Demonstrated genomic effects of 1,25(OH)2D  include promotion of factors involved 
in myogenesis (desmin, myogenin and IGF2) and inhibition of factors that negatively 
regulate muscle mass (myostatin, proliferating cell nuclear antigen) with an overall 
effect of increased muscle fibre size and diameter in C2C12 myoblasts (Garcia, King 
et al.).  European Sea Bass treated with varying doses of cholecalciferol show a dose 
dependant increase in white muscle fibre size and amount (Alami-Durante, Cluzeaud 
et al. 2011). 
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1.13:  Animal models 
 
VDR knockout mice have a 20% reduction in size of all fibre types compared to wild 
type controls, and show persistent upregulation of myogenic regulatory factors which 
are involved in growth and differentiation of myocytes and are normally down-
regulated in mature muscle (Endo, Inoue et al. 2003).  These mice have also been 
shown to have abnormal swim behaviour when compared to wild type mice with 
slower recovery (Kalueff, Lou et al. 2004; Burne, Johnston et al. 2006; Minasyan, 
Keisala et al. 2009).  Other tests of motor co-ordination also show impairment in 
VDR knockout mice.  However it is difficult to pinpoint the cause of their disabilities 
as they systemically lack the VDR receptor and may have neurological and cardiac 
dysfunction as well as skeletal muscle issues.  
 
1.14:  Human studies of Vitamin D status and Muscle Function 
 
1.14.1:  Cross-sectional Studies 
 
A number of studies have supported a link between vitamin D status and skeletal 
muscle function in the elderly (Dhesi, Bearne et al. 2002; Zamboni, Zoico et al. 2002; 
Bischoff-Ferrari, Dietrich et al. 2004; Stewart, Alekel et al. 2009; Houston, Tooze et 
al. 2011) but there are also a number of negative studies published (Stein, Wark et al. 
1999; Annweiler, Beauchet et al. 2009).  There is a wide variation in cut off values 
used for serum 25(OH)D concentration, as well as variation in outcome measures 
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which include the ‘sit to stand test’, physical performance score, falls, handgrip and 
quadriceps strength which may explain the conflicting results found.   
 
1.14.2:  Supplementation Studies 
 
 Interventional studies looking at potential benefits of Vitamin D supplementation on 
muscle strength have also been extremely variable with regards to dose and duration 
of vitamin D supplementation given and techniques used for assessing muscle 
function and have therefore unsurprisingly shown conflicting results. Meta-analyses 
have also been difficult to carry out and interpret for the same reasons.   
 
Only a small number of intervention studies published have used established 
measures of muscle strength.  Dhesi et al randomised 139 patients with a history of 
falls and low serum 25(OH)D concentration (<12μg/l) to receive 600,000 iu of 
ergocalciferol im or placebo and used QMVC as one of their outcome measures.  No 
difference was seen after 6 months in QMVC between placebo and control although 
changes were seen in other measures of physical performance (Dhesi, Jackson et al. 
2004).  Zhu et al again recruited those with a history of falls and low serum vitamin D 
concentration (<20ng/ml) to have 1,000 IU ergocalciferol or placebo with calcium for 
1 year.  They demonstrated an improvement in hip muscle strength in those with 
lower baseline  serum 25(OH)D concentration (Zhu, Austin et al. 2010).  A Chilean 
study recruited community dwelling older subjects with serum 25(OH)D 
concentration < 16ng/ml to have 400iu cholecalciferol with calcium daily vs. calcium 
only in an exercise intervention group vs. a non-exercise group.  They measured 
QMVC and handgrip strength and found improvement with both training groups, but 
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not with vitamin D supplementation either with or without training.  However they 
did find an improvement in other functional measures as well as bone mineral density 
scores (Bunout, Barrera et al. 2006).  Another German study recruited 242 elderly 
subjects with serum 25(OH)D concentration < 78nmol/l and randomised them to 
receive 800iu of cholecalciferol + calcium per day vs calcium alone for 1 year and 
carried out their follow up assessments 8 months later.  They found a significant 
decrease in the number of falls and also an improvement in quadriceps strength in the 
Vitamin D supplementation group (Pfeifer, Begerow et al. 2009). 
 
A recent meta-analysis of 13 randomised controlled trials (RCTs) involving elderly 
subjects who were vitamin D deficient or insufficient concluded that improvements in 
muscle strength were seen in studies with daily doses of 800-1000i u.  An 
improvement in balance was also found, but no effect on gait (Muir and Montero-
Odasso 2011).   
 
Two relatively recent studies have looked at Vitamin D supplementation in patients 
with COPD and potential benefits on muscle strength.  Hornikx et al retrospectively 
analysed a subgroup of patients who took part in a trial looking at Vitamin D 
supplementation and exacerbation rate in COPD.  This subgroup of patients 
underwent pulmonary rehabilitation and 50% were given high dose vitamin D 
supplementation and 50% received a placebo.  The serum 25(OH)D concentration 
was increased in those receiving supplements, and significant improvements were 
seen in inspiratory muscle strength and maximal oxygen uptake.  Improvements were 
also seen in QMVC and walking distance but these did not reach statistical 
significance (Hornikx, Van Remoortel et al. 2012).  Bjerk et al carried out a pilot 
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study on 36 subjects with GOLD stage III and IV COPD, giving 2000iu of 
cholecalciferol vs placebo for 6 weeks only.  They found no significant difference in 
the Short Physical Performance Battery Test or improvement in the St George’s 
Respiratory Questionnnaire (SGRQ) despite a demonstrated increase in 25(OH)D 
serum concentration (Bjerk, Edgington et al. 2013).  Taken together, these results 
suggest that some improvements may be seen with vitamin D supplementation in 
subjects with COPD who are vitamin D deficient, if given high dose supplementation 
for a prolonged period of time. 
 
1.14.3:  Biopsy studies 
 
A number of biopsy studies in the 1970’s of subjects with renal failure or those 
documented as having osteomalacia have shown relatively consistent findings of 
either ‘non-specific’ or type II muscle fibre atrophy (Floyd, Ayyar et al. 1974; Dastur, 
Gagrat et al. 1975; Irani 1976; Yoshikawa, Nakamura et al. 1979).  Two 
supplementation studies in different subsets of patients (bone loss of ageing and 
osteomalacia) have shown an increase in the proportion and size of Type IIa muscle 
fibres with vitamin D supplementation although serum 25(OH)D concentration was 
not measured (Dastur, Gagrat et al. 1975; Sorensen, Lund et al. 1979). 
 
Only one randomised controlled trial of vitamin D supplementation, which included 
muscle biospies, has been carried out on post stroke hemiplegic patients with severe 
vitamin D deficiency, which showed an increase in type II fibre proportion and size 
after 2 years of vitamin D supplementation in the treatment group, but not the placebo 
(Sato, Iwamoto et al. 2005). 
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1.15:  Vitamin D status and lung function 
 
The 3
rd
 National Health and Nutrition survey (NHANES) was a large US population 
based study involving over 14,000 people.  It demonstrated convincing evidence that 
serum 25(OH)D concentration was independently associated with both FEV1 and 
FVC (Black and Scragg 2005).  Between the lowest and highest quartiles of serum 
25(OH)D concentration, there was a difference of 126mls in FEV1 and 172mls in 
forced vital capacity (FVC), after correcting for confounding factors.   
 
However not all studies have confirmed this association: Shaheen et al failed to 
demonstrate an association between adult lung function and serum 25(OH)D in a 
large cross sectional study (Shaheen, Jameson et al. 2011) 
   
1.16:  Serum 25(OH)D concentration in COPD 
 
Over half of the elderly population in the UK and USA have vitamin D deficiency 
depending on the definition used (Holick 2007; Hypponen and Power 2007).  Current 
debate is still ongoing about the optimal definition of vitamin D deficiency, which 
could be based on levels required to suppress PTH, levels required for optimal 
calcium absorption in the intestine and levels required to maintain bone mineral 
density (BMD) and prevent falls and fractures.  Current consensus is that a serum 
25(OH)D concentration greater than 75nmol/l  is required for optimal bone health 
(Dawson-Hughes, Heaney et al. 2005).  Factors associated with serum 25(OH)D 
concentration in normal subjects are sunlight exposure, latitude, season, skin type, 
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dietary intake of vitamin D, BMI  and genetic influences, in particular polymorphisms 
in the vitamin D binding protein (Hypponen and Power 2007)
,
(Lauridsen, Vestergaard 
et al. 2005; Taes, Goemaere et al. 2006; Ahn, Yu et al. 2010). 
 
In the United Kingdom, sunlight is only sufficiently strong enough to produce 
cholecalciferol in the skin between April and November (Webb and Engelsen 2006).  
A recent study in city dwelling subjects in the UK suggests that current 
recommendations for brief episodes of sun exposure in the summer months will place 
most people in the ‘sufficient’ range of serum 25(OH)D concentration, but not the 
optimal range above 75nmol/l.  COPD patients are less active (Pitta, Troosters et al. 
2005) and spend less time outdoors (Donaldson, Wilkinson et al. 2005; Baghai-
Ravary, Quint et al. 2009) compared to healthy elderly subjects due to breathlessness 
and leg fatigue.  They are therefore less likely to have adequate sunlight exposure 
although this has not been measured directly.  They can also have poor nutritional 
intake, particularly with severe disease.  One study in Spain showed that only 4% of 
COPD subjects consumed the recommended daily intake of 10μg of vitamin D (de 
Batlle, Romieu et al. 2009).  These factors combined put them at increased risk of 
having vitamin D deficiency. 
 
One published cross-sectional study has looked at serum 25(OH)D concentration 
specifically in COPD patients compared to a control population (Janssens, Bouillon et 
al. 2010).  They found that COPD patients had significantly lower serum 
concentration of 25(OH)D, and that 25(OH)D concentration decreased with 
increasing GOLD (Global initiative for chronic obstructive lung disease) Stage.  The 
control population consisted of smokers and ex smokers who were matched for age 
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and sex, and no subjects were taking any vitamin D supplementation.  This evidence 
is supported by an earlier study looking at serum 25(OH)D concentration in patients 
with severe lung disease who were referred for lung transplant, of whom 
approximately 50% had a diagnosis of COPD (Forli, Bjortuft et al. 2009).  Although 
there was no control group, subjects had particularly low levels of 25(OH)D 
(38nmol/l). 
 
1.17:  Evidence for a link between vitamin D status and skeletal muscle dysfunction 
in COPD 
 
No studies published prior to this research being carried out looked at serum 
25(OH)D concentration in relation to muscle function in COPD.  One study looked at 
polymorphisms in the VDR and found an association between the fokI polymorphism 
and muscle strength in COPD patients and control subjects. People with the C allele, 
which produces a shorter protein product, had a reduced quadriceps strength when 
compared to those with one or more T alleles, and this supports previous findings in 
healthy elderly men (Roth, Zmuda et al. 2004).  Interestingly, the shorter allele has 
been associated with an increased risk of type I diabetes, and human monocytes 
homozygous for the short VDR protein product express higher levels of IL-12 protein 
and mRNA (van Etten, Verlinden et al. 2007).  Thus it is possible that the reduced 
muscle strength associated with the C allele is due to an exaggerated response to 
inflammatory stimuli in muscle.   
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1.18:  Osteoporosis and Osteopenia 
 
Recent studies have shown a consistently high prevalence of osteoporosis and 
osteopenia in patients with COPD.  A systematic review showed that osteoporosis 
occurred in 9 to 69% of patients, and osteopenia in  27 to 67%, with an overall mean 
prevalence of osteoporosis from 13 studies, involving 772 patients, of 35.1% (Graat-
Verboom, Wouters et al. 2009).  Four studies included in this review compared COPD 
patients and age matched healthy control subjects and there was a significant 
difference in prevalence: 32.5% in COPD vs. 11.4% in healthy controls. Interestingly, 
the prevalence of osteoporosis in COPD appears to be higher than in some other 
chronic lung diseases, including those involving chronic corticosteroid use, such as 
idiopathic pulmonary fibrosis (Aris, Neuringer et al. 1996; Katsura and Kida 2002; 
Tschopp, Boehler et al. 2002).   
 
Factors which are consistently related to osteoporosis in multivariate analyses are age, 
sex, BMI and other anthropometric measurements, lung function and corticosteroid 
use (Scanlon, Connett et al. 2004; Kjensli, Mowinckel et al. 2007; Vrieze, de Greef et 
al. 2007).   
 
As well as the morbidity and mortality associated with hip and wrist fractures, of 
particular relevance in COPD patients are vertebral compression fractures (VCFs). 
These cause kyphosis which has a detrimental effect on lung function (Leech, 
Dulberg et al. 1990; Schlaich, Minne et al. 1998)  A prospective study of 245 COPD 
patients in Canada looked at the prevalence of VCFs seen on chest x-ray (CXR) and 
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found it to be 9% (Majumdar, Villa-Roel et al. 2010).  BMI was the only variable 
independently associated with incidence of VCF. 
 
Low serum 25(OH)D contributes to the development of osteopenia and osteoporosis 
as there is reduced calcium absorption from the gut, and both PTH and 1,25(OH)D2 
increase bone resorption to maintain calcium levels (Suda, Ueno et al. 2003).  Vitamin 
D supplementation in elderly people, when given with calcium, has been shown to 
improve BMD and reduce the risk of falls and fracture (Chapuy, Pamphile et al. 2002; 
Boonen, Lips et al. 2007; Abrahamson, Masud et al. 2010), although one study giving 
annual high dose  cholecalciferol showed an increased risk of falls compared to 
placebo (Sanders, Stuart et al. 2010) suggesting that dosing regimen is an important 
factor.  The reduction in fracture risk may be due to a combination of increases in 
BMD and indirectly through increases in muscle strength and a reduction in falls. 
 
It is possible therefore that Vitamin D deficiency may contribute to the increased 
prevalence of osteoporosis and osteopenia seen in COPD.  Only one study has looked 
at the effect of serum 25(OH)D concentration on BMD in COPD patients and found 
no relationship between them.  They compared BMD in 49 COPD and 40 healthy 
control subjects and found it to be significantly lower in COPD patients in the lumbar 
spine, femoral neck and total femur.  However other parameters were only measured 
in COPD patients. FEV1 (l) and weight were independently associated with BMD in 
the multivariate model which included corticosteroid use and serum 25(OH)D 
concentration (Franco, Paz-Filho et al. 2009).   
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1.19:  Other connections between Vitamin D status and COPD 
 
1.19.1:  Inflammation 
 
1,25(OH)2D is an important modulator of the innate and adaptive immune systems.  
The VDR is expressed in most cells of the immune system including macrophages, 
dendritic cells, neutrophils, B cells and activated CD4
+
 and CD8
+
 T cells (Baeke, 
Takiishi et al. 2010).  There are two important roles that 1,25(OH)2D has in the 
regulation of the immune system which are likely to have an impact on the 
development and progression of COPD. 
 
 
In the innate immune system, 1,25(OH)2D stimulates the production of cathelecidin.  
This is an anti-microbial peptide which has broad spectrum activity against bacterial 
and viral pathogens. It acts as a chemo attractant for various inflammatory cell types, 
and is involved in epithelial proliferation and repair, and angiogenesis(Hiemstra 
2007).  1,25(OH)2D has activity against Mycobacterium tuberculosis, an action which 
has now been shown to be mediated by cathelecidin (Martineau, Wilkinson et al. 
2007) .  More importantly, for subjects with COPD, cathelecidin has also been shown 
to have activity against Pseudomonas aeruginosa and Escherichia coli (Wang, Nestel 
et al. 2004) 
 
Another important role of 1,25(OH)2D in the immune system is that of T cell 
regulation.  1,25(OH)2D has been identified to play an important role in maintaining T 
cell balance.  It alters transcription of IL-2, interferon gamma (IFNγ) and IL-4 and has 
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been shown to directly influence CD4
+
 cells to suppress Th1 and promote Th2 
differentiation (Alroy, Towers et al. 1995; Boonstra, Barrat et al. 2001).  More 
recently it has been demonstrated that 1,25(OH)2D suppresses production of IFNγ, IL-
17 and IL-21 by CD4
+
 cells, and following 1,25(OH)2D treatment, T cells adopted 
functional and phenotypic properties of regulatory T cells (Tregs), expressing high 
levels of FoxP3 (Jeffery, Burke et al. 2009).   These latter actions have important 
implications on auto immune disorders such as diabetes and inflammatory bowel 
disease and may be relevant to autoimmune processes in COPD.  The lungs of 
subjects who smoke but have normal lung function have been shown to have higher 
levels of Tregs than those who have never smoked, and compared to smokers who 
have developed COPD (Barcelo, Pons et al. 2008).  Studies in mice have 
demonstrated an inflammatory airway response mediated by Th17 cells and 
characterised by increased neutrophilic inflammation and B cell influx, which was 
suppressed by the co- transfer of Tregs (Jaffar, Ferrini et al. 2009).  Taken together, it 
appears that functional regulatory T cells may protect against the development of 
COPD by controlling the T cell response to immune stimuli.  
 
The actions of 1,25(OH)2D on the immune system are likely to be of relevance to the 
occurrence of respiratory infection and exacerbations in COPD.    However two 
recently published studies found no association between serum 25(OH)D 
concentration at baseline and time to first exacerbation or exacerbation frequency 
(Kunisaki, Niewoehner et al. 2012; Quint, Donaldson et al. 2012), and one 
supplemental study found only a reduction in exacerbations with supplementation in 
those with baseline 25(OH)D <10ng/ml (Lehouck, Mathieu et al.). 
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1.19.2:  Cardiovascular Disease 
 
25(OH)D and 1,25(OH)2D are also implicated in the development of cardiovascular 
disease.  In 1α-hydroxylase knockout mice, increased blood pressure, activation of the 
renin-angiotensin system, myocardial hypertrophy and decreased cardiac function are 
seen which are prevented by the administration of 1,25(OH)2D (Goltzman 2010).   
 
In human studies, low levels of serum 25(OH)D have been associated with increased 
risk of hypertension (Forman, Curhan et al. 2008) and cardiovascular disease 
(Kendrick, Targher et al. 2009), and 8 weeks of vitamin D and calcium 
supplementation have been shown to reduce systolic blood pressure compared to 
calcium alone (Pfeifer, Begerow et al. 2001).  A number of large supplemental trials 
of Vitamin D are currently underway to try and clarify potential benefits of Vitamin D 
supplementation on cardiovascular outcomes. 
 
1.19.3:  Cancer Risk 
 
Several epidemiological studies have associated low serum 25(OH)D concentration 
with increased risk of colorectal, breast and prostate cancer risk (Giovannucci 2005).  
However its effects in lung cancer have not been clearly demonstrated.  VDR 
polymorphisms have been associated with the incidence of lung cancer (Dogan, Onen 
et al. 2009) and in vitro cell studies have shown that 1,25(OH)2D has anti cancer 
effects such as suppression of angiogenesis and cell proliferation (Giovannucci 2005).  
Mouse studies have shown a protective effect of 1,25(OH)2D against metastases in 
lung cancer (Nakagawa, Kawaura et al. 2004).  However epidemiological data in 
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human studies has not shown an association between low serum 25(OH)D 
concentration and lung cancer (Kilkkinen, Knekt et al. 2008). 
 
1.19.4:  Ageing 
 
COPD has been hypothesised to be a disease of ageing (Ito and Barnes 2009) and 
evidence which supports this hypothesis is discussed above.  1,25(OH)2D also 
controls many genes involved in aging (Haussler, Haussler et al. 2010) and in human 
studies, higher serum 25(OH)D concentrations have been associated with longer 
telomere length even after adjustment for age and other confounding factors (Liu, 
Prescott et al.; Richards, Valdes et al. 2007).  Biopsy studies in humans have shown 
that VDR concentrations in skeletal muscle (Bischoff-Ferrari, Borchers et al. 2004) 
and duodenum (Ebeling, Sandgren et al. 1992) decrease with age and it is possible 
that decreased concentrations may be present in COPD patients causing a relative 
resistance to 1,25(OH)2D which may be the link to accelerated aging in COPD. 
 
 
1.20:  Genetic influences on skeletal Muscle strength 
 
As well as on lung function itself, genetic influences also appear to be important with 
regards to skeletal muscle function in COPD.  The VDR FokI polymorphism has been 
associated with muscle strength in both COPD and healthy subjects, whilst the VDR 
Bsm polymorphism is associated with strength only in a COPD population 
(Hopkinson, Li et al. 2008).  The ACE I/D polymorphism is also associated with 
strength in COPD subjects (Hopkinson, Nickol et al. 2004). 
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1.21:  Research Questions 
 
In summary, 1,25(OH)2D has important actions in skeletal muscle, and subjects with 
COPD are known to develop skeletal muscle dysfunction which appears to be 
multifactorial although reduced physical activity plays a significant role.  COPD 
subjects have been demonstrated to have a lower serum 25(OH)D concentration, 
Hopkinson et al demonstrated an effect of polymorphisms in the VDR and skeletal 
muscle strength in both COPD and healthy subjects and there are a significant number 
of co morbidities in COPD that are linked to Vitamin D status.   
 
This research was therefore carried out to try and answer the following questions: 
 
(1)  Is Vitamin D status a contributing factor to skeletal muscle dysfunction in COPD? 
 
(2)  What are the potential molecular pathways through which 25(OH)D and 
1,25(OH)2D may influence skeletal muscle strength? 
 
(3)  Do polymorphisms in genes involved in Vitamin D metabolism and the 
Angiotensin pathway influence serum 25(OH)D concentration and / or skeletal 
muscle strength in COPD?  
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A cross sectional clinical study was undertaken which compared serum 25(OH)D and 
1,25(OH)2D concentrations, and skeletal muscle strength in COPD subjects with an 
age and sex matched control population and this is described in Chapter 3. 
 
A smaller sub-study was carried out in subjects who underwent a muscle biopsy to 
investigate whether associations between serum 25(OH)D and 1,25(OH)2D 
concentrations, myogenic regulatory factor mRNA expression and muscle fibre type 
mRNA expression at a molecular level were similar in COPD and control subjects, 
and also looked at VDR protein concentrations in skeletal muscle.  This is described 
in Chapter 4. 
 
Genetic influences of polymorphisms in genes affecting Vitamin D metabolism and 
the renin-angiotensin system on serum 25(OH)D concentration and skeletal muscle 
strength were investigated and these are described in Chapter 5. 
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Chapter 2: Description of Methods 
 
2.1:  Ethical Approval 
 
All subjects included in this work provided informed written consent and the study 
was approved by the Ethics Committee of The Royal Brompton Hospital.  The study 
was registered on the UKCRN clinical trials register, number 6551. 
 
2.2:  Power Calculations 
 
For the cross sectional clinical study, a power calculation was performed by Michael 
Roughton at Imperial College, which suggested that a sample size of 100 was required 
to give an 80% power of detecting an r
2
 correlation of 0.37 assuming a SD of 12.5 kg 
for quadriceps maximum voluntary contraction strength and of 17iu for vitamin D 
level. 
 
2.3:  Statistical Analysis 
 
Statistics were analysed using SPSS for windows version 20.0 and STATA Release 
10.1.  Descriptive statistics are reported as mean (standard deviation) for parametric 
data, and median (range) for non-parametric data.  T tests were used to compare 
means for parametric data and the Mann-Whitney test for non-parametric data.  The 
Spearman rank test was used for correlations.  Stepwise logistic regression was used 
to establish clinical factors influencing muscle strength.  Regression with robust 
variances was used to compare endurance curves between COPD and control groups, 
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and to compare vitamin D sufficient and insufficient subjects within groups.  A p 
value <0.05 was considered significant.   
 
For the work looking at genetic polymorphisms, stepwise logistic regression was used 
to look for factors influencing muscle strength and serum 25(OH)D levels.  To look 
for gene - gene interactions, a hierarchy of models was used.  A p value of <0.01 was 
considered significant. 
 
2.4:  Study Subjects 
 
Stable COPD patients were recruited from outpatient clinics and from the 
department’s clinical database.  
Inclusion criteria were as follows: 
1) FEV1/FVC < 70% 
2) Significant smoking history 
 
Exclusion criteria were as follows: 
1) exacerbation within the preceding 3 months 
2) uncontrolled heart failure 
3) NIDDM 
4) Primary musculoskeletal problem eg previous polio 
5) malignancy 
 
Control subjects were recruited by advertisement (figure 2.1), through a local 
community group for the elderly, and through collaboration with other research 
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groups. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1:  Advertisement used to recruit healthy control subjects 
  
Inclusion criteria: 
1) FEV1/FVC > 70%  
2) FVC > 70% predicted 
 
Exclusion criteria were as follows: 
1) uncontrolled heart failure 
2) NIDDM 
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3) Primary musculoskeletal problem eg previous polio 
4) malignancy 
 
 Subjects were screened via a telephone call and if suitable, invited to attend the 
skeletal muscle laboratory for further assessment.  95% of control subjects who were 
screened were able to take part in the study.  A small number of these (n=6) were 
diagnosed with GOLD stage I COPD and therefore included in the COPD arm of the 
study.  90% of COPD subjects screened via telephone took part in the study. 
 
Study participants were sampled throughout the year, and there was no difference in 
the time of year measured between the patient and control groups.  A systematic 
history including exacerbation rate and average daily dose (ADD) of oral 
corticosteroids in the preceding year was performed.   
 
2.5:  Dietary Vitamin D Intake 
 
We included subjects who were taking Vitamin D supplementation which could 
include prescribed Vitamin D3 supplementation or cod liver oil.  We assessed total 
weekly Vitamin D intake using a recall questionnaire (figure 2.2) developed by 
ourselves based on known dietary sources of vitamin D (Holick 2007).  There is 
currently no standardised way of assessing vitamin D dietary intake, which may be 
due to the fact that our main source of Vitamin D is through the action of sunlight on 
the skin.  We could not directly measure sunlight exposure but it is known that COPD 
subjects spend less time out of doors and dietary sources of Vitamin D are likely to be 
more relevant for them.  
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Food IU’s per 
serving 
Servings per 
week 
IU’s per 
week 
Cod liver oil, 1 tablespoon 1,360   
Salmon, cooked, 3.5 ounces 360   
Mackerel, cooked, 3.5 ounces 345   
Tuna, canned in oil, 3 ounces 200   
Sardines, canned in oil, 1.75 
ounces 
250   
Margarine, fortified, 1 
tablespoon 
60   
Cereal, fortified 10% DV 40   
Egg (whole) 20   
Liver, beef, cooked 3.5 ounces 15   
Cheese, 1 ounce 12   
Total (per week)    
 
Table 2.2:  Dietary Vitamin D assessment 
 
2.6:  Health-Related Quality of Life 
 
Health-related quality of life is a tool for assessing patients own perception of their 
disease and how their symptoms affect them.  It complements clinical assessment and 
other measures of physical function.  A number of questionnaires have been 
developed and validated to assess health-related quality of life, some of which are 
disease specific.  
 
In this thesis we used the St George’s Respiratory Questionnaire to assess health-
related quality of life in COPD subjects.  The SGRQ is a 76-item supervised self-
administered questionnaire. Patients complete it without conferring with anyone else, 
but the investigator is available to clarify the meaning of questions. Standard answers 
to potential patient queries are given in an accompanying manual. Three component 
scores are calculated: symptoms, activity, and impacts (on daily life), and a total 
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score. These four scores can range from 0 to 100 with a high score representing worse 
quality of life (QOL). It has been validated in COPD in terms of repeatability and 
correlation with appropriate clinical measures including MRC (medical research 
council) dyspnoea score, presence of wheeze, six minute walk distance, anxiety-
depression and cough. (Jones, Quirk et al. 1992)  It is strongly associated with arterial 
oxygen tension (PaO2) (Okubadejo, Jones et al. 1996) and FEV1 (Ferrer, Alonso et al. 
1997; Jones 2001), as well as hospital readmission rates (Osman, Godden et al. 1997), 
and has been shown to deteriorate with exacerbations (Seemungal, Donaldson et al. 
1998)  More importantly, it has been shown to be a predictor of mortality in COPD 
independent of lung function and age, with the SGRQ activities score being most 
strongly associated with mortality in a 5 year follow up study with a relative risk of 
1.038 (p=0.0001) (Oga, Nishimura et al. 2003). 
 
2.7:  Yale Physical Activity Survey (YPAS) 
 
Daily physical activity can be assessed either directly with a variety of activity 
monitors or indirectly through questionnaires.  The former gives a more accurate 
assessment of daily activity but involves a prolonged period of monitoring and at least 
2 study visits for a subject which was not practical for this cross sectional study.  The 
YPAS was therefore used to assess daily physical activity in both patient and control 
groups. 
 
The YPAS is an interviewer administered survey that asks the individual to estimate 
time spent in a list of 25 activities in a typical week during the last month.  These 
activities are categorised into work, yard work, care taking, exercise and recreational 
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activities.  Time spent in each activity is multiplied by an intensity code (kcal·min
-1
) 
and then summed across all activities to create an index of weekly energy 
expenditure (kcal·wk
-1
).  In addition, time spent in each activity is summed to 
provide a total time index (h·wk
-1
).  Individuals are also asked to estimate the 
number of hours spent in five distinct physical activity dimensions.  Specifically, 
they are asked to categorise the frequency and duration of vigorous activity, leisurely 
walking, moving, standing and sitting.  Weights are assigned to each category 
(vigorous activity: 5; leisurely walking: 4; moving: 3; standing: 2; sitting: 1). The 
frequency score and duration score are multiplied together and then multiplied again 
by each dimension’s weighting factor to calculate an index for each dimension. A 
summary index is the sum of the five individual indices. 
This questionnaire was designed and validated in 1993 to assess physical activity in 
older people.  In the validation study (n=25), the YPAS index of vigorous activity 
correlated positively with estimated maximal oxygen consumption (VO2max) (r=0.60; 
P=0.003), whilst the weekly energy expenditure (r=-0.47; P=0.01) and daily hours 
spent sitting (r=0.53; P=0.01) correlated with resting diastolic blood pressure 
(Dipietro, Caspersen et al. 1993)  Similar findings were reported in a subsequent 
larger validation study (n=69) which again showed a correlation of various YPAS 
measures with VO
2
max (summary, moving and standing indices) (Young, Jee et al. 
2001)  The YPAS is a useful tool in comparing physical activity between populations 
(Lindamer, McKibbin et al. 2008) and has been previously used to compare COPD 
and control populations (Swallow, Gosker et al. 2007). 
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2.8:  Body Composition 
 
Height was measured to the nearest cm using a wall mounted height bar.  Subjects 
were not wearing shoes. Weight was measured using Tanita TBF-305 single-point 
load cell electronic scales (Tanita Corporation, Illinois, USA). Subjects were lightly 
dressed.  BMI was also calculated (weight/height
2
). 
 
FFM was determined using bioelectrical impedance analysis. This technique uses the 
electrical impedance of body tissues to determine an estimate of total body water 
since electricity is conducted by dissolved ions. A two-compartment model is used, 
which assumes that adipose tissue contains no water and that the fat free mass is of 
particular percentage water, from which fat free mass can be derived. A number of 
equations have been produced based on the relationship that fat free mass is 
proportional to height
2
/resistance. Weight, height, gender, age and habitual physical 
activity have all been found to influence this relationship.  
 
In COPD, equations validated in healthy populations tend to over-estimate FFM. 
Disease specific equations have been validated against other techniques for assessing 
body composition including deuterium dilution dual energy x-ray absorptiometry 
(DEXA), hydrodensitometry and skin fold anthropometry (Schols, Wouters et al. 
1991).  
 
The equations for calculating FFM used in this thesis were those of Steiner et al 
(Steiner, Barton et al. 2002) which have been validated against DEXA and 
incorporate weight, height and gender. 
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Males: FFM (kg) = 8.383+((0.465*Height
2 
(cm) / resistance (ohm))+(0.213*Weight 
(kg)) 
Females: FFM (kg) = 7.610+((0.474*Height
2 
(cm) / resistance (ohm))+(0.184*Weight 
(kg)) 
 
Fat free mass index (FFMI) was calculated by dividing FFM by height in metres 
squared. By convention, a value of <15 kg/m
2
 for women or <16 kg/m
2
 for men is 
considered to represent nutritional depletion. 
 
 
Figure 2.3: Measurement of bioelectrical impedance 
 
Bioelectrical impedance was measured using a Bodystat 1500 device (Bodystat, Isle 
of Man, UK). Subjects were supine, with arms and legs abducted so that they were not 
touching the subject’s body or each other. Biotab Ag/AgCl electrodes (Maersk 
Medical, Stonehouse, UK) were placed on the hand behind the knuckle of the middle 
finger and on the wrist next to the ulnar head, as well as on the foot behind the 2
nd
 toe 
and on the inter-malleolar line on the dominant side (figure 2.3). The device was 
calibrated regularly using a calibration unit of known impedance provided by the 
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manufacturer.  
 
2.9:  Respiratory Muscle Strength 
 
Sniff nasal inspiratory pressure (SNiP) is a volitional non-invasive technique for 
assessing respiratory muscle strength.  A plug is inserted into one nostril which is 
attached to a pressure transducer via a polyethylene tube.  Subjects are asked to 
perform a maximal sniff manoeuvre through the contra-lateral nostril and the pressure 
is recorded.  Measurements are repeated until reliable repeated values are seen which 
may take up to 10 repeats. 
 
This technique was developed as an alternative to invasive measures of respiratory 
muscle function and has been validated against sniff oesophageal pressures in normal 
subjects as well as those with respiratory muscle weakness (Heritier, Rahm et al. 
1994).  
 
2.10:  Handgrip Strength 
 
Handgrip strength was measured using a Jamar handgrip dynamometer (Sammons 
Preston Rolyan, Bolingbrook, IL).  In accordance with the American Society of Hand 
Therapy recommendations, subjects were seated with their shoulders in 00 abduction 
and neutral rotation, their elbow in 900 of flexion, and their forearms in neutral 
pronation / supination (Fess 1992).  Subjects performed 6 maximal contractions 
alternating hands with a rest of 30 seconds in between.  The maximal value of the 
dominant hand was used.  This technique has been shown to be a reliable 
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measurement in older community dwelling adults (Bohannon and Schaubert 2005). 
 
 
2.11:  Quadriceps Strength 
 
Quadriceps strength can be measured using the volitional technique of Edwards et al 
(Edwards, Young et al. 1977), or by using a magnetic impulse to supra-maximally 
stimulate the femoral nerve (Polkey, Kyroussis et al. 1996).  Both techniques were 
used in this thesis and are described below. 
 
For the measurement of Quadriceps maximum voluntary contraction, (QMVC), 
subjects sat in a modified chair with an inextensible strap connecting the ankle of their 
dominant leg to a strain gauge (Stainstall Ltd, Cowes, UK).  The signal was amplified 
and passed to a computer running LabView4 software (National Instruments, Austin, 
Texas).  The linearity of the strain gauge is factory certified from 0-100kg.  The 
equipment was calibrated using a suspended weight for each subject.  To ensure that 
the contraction was isometric, the subject’s knees were aligned at 90 degrees, and the 
strain gauge and couplings were also aligned.  Subjects performed a minimum of 3 
sustained maximal isometric quadriceps contractions of 5-10 seconds duration.  The 
force produced was visible online to both subject and investigator to allow positive 
feedback and vigorous encouragement was given.  A gap of at least 30 seconds was 
left between contractions to allow time to recover.  The maximum strength (kg) 
sustained for 1 second was measured for each contraction and the average of 3 
contractions with a variability of less than 5% was used for each subject.    
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Unpotentiated twitch quadriceps force (TwQu) was assessed by magnetic femoral 
nerve stimulation according to the technique described by Polkey et al (figure 2.4).  
Subjects were seated in the same modified chair described above with the ankle of 
their dominant foot in a strap attached to the strain gauge in an isometric position.  
However they were now in a supine position and their leg was rested for 20 minutes 
to allow the muscle to depotentiate.  Stimulation was performed using two Magstim 
200 monopulse units discharged simultaneously through a 70mm branding iron coil. 
This combination delivers an output approximately equivalent to 120% of the output 
of a single unit.  The coil is pressed firmly over the femoral nerve high in the femoral 
triangle and discharged.  The twitch force produced is recorded using the equipment 
described above.  A 30 second gap between potentiations is required to avoid ‘twitch 
on twitch’ potentiation.  The position was initially adjusted and then a stimulus 
response curve was generated to ensure supramaximality of stimulation with 3 stimuli 
at 80, 85, 90, 95 and 100% of stimulator output in random order.  The mean of at least 
5 stimulations at 100% stimulator output was taken.  Supramaximality using this 
technique has been demonstrated previously (Polkey, Kyroussis et al. 1996; Harris, 
Polkey et al. 2001; Schonhofer, Zimmermann et al. 2003) 
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. 
Figure 2.4:  Non-volitional assessment of quadriceps strength 
 
2.12:  Quadriceps Endurance 
 
Quadriceps Endurance was measured using the technique described by Swallow et al 
(Swallow, Gosker et al. 2007) (figure 2.5). The subject is seated on the same modified 
apparatus as detailed above in a reclining position, with the ankle of their dominant 
leg attached to the strain gauge in an isometric position with the ankle strap. A 
Magstim Rapid flat oval and flexible magnetic coil was wrapped around the 
quadriceps muscle and fastened into place. The coil consists of an elliptical shaped 
coil with nine concentric insulated copper rings encased in silicone. A space is left 
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between the exterior of the insulation and the silicone to allow pumping of a cooling 
fluid, 3-ethoxy-1,1,1,2,3,4,4,5,5,6,6,6-dodecafluoro-2-triflouromethyl-hexane. The 
stimulator was set at a frequency of 30 Hz, a duty cycle of 0.4 (2 s on, 3 s off), and for 
50 trains (250 s). The stimulator intensity was adjusted for each subject so as to 
initially generate 20% of their supine QMVC.  The quadriceps force produced with 
each stimulation was recorded with the same equipment as described previously.  The 
maximum force produced during each train was measured manually. Endurance was 
then calculated as the time taken for the force produced to decline to 70% of baseline 
force.  
 
 
Figure 2.5:  Quadriceps endurance measurement 
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Other methods of measuring quadriceps endurance involve repetitive maximal 
voluntary contractions which can be difficult to maintain and depend on patient effort.  
Electrical stimulation has also been used but is less well tolerated by patients than 
magnetic stimulation (Han, Shin et al. 2006).  The above technique was developed 
with patient tolerability in mind and has been shown to be repeatable (Swallow, 
Gosker et al. 2007).  Repetitive magnetic stimulation has also now been trialled as a 
method for training the quadriceps muscle in subjects with severe COPD limited by 
dyspnoea with positive results on muscle strength, 6 minute walk distance and quality 
of life (Bustamante, Lopez de Santa Maria et al.) 
 
2.13:  Pulmonary Function Testing 
 
COPD subjects had full lung function tests performed by technicians working in the 
Lung Function Department of the Royal Brompton Hospital. Spirometry was obtained 
using a heated pneumotachograph with flow integration, lung volumes by whole body 
plethysmography and gas transfer with a single breath technique (Compact Master lab 
system, Jaeger, Germany). Predicted values used are those of the European Coal and 
Steel Community (Quanjer, Tammeling et al. 1993). The equipment is regularly 
calibrated and the tests were performed in accordance with the British Thoracic 
Society Guidelines (1994). 
Control Subjects had spirometry measured according to British Thoracic Society 
Guidelines (1994)) using a handheld spirometer (MicroLab 3500 Mk 8, Micromedical 
Ltd, Warwick, UK). 
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2.14:  Serum Analysis 
 
Whole blood was collected in lithium heparin and immediately spun in a centrifuge at 
800 RPM for 20 minutes.  The supernatant was removed into a new sterile container 
and stored at -80
0 
C. Batch analysis was then performed for 25(OH)D, 1,25(OH)2D, 
high sensitivity c-reactive protein (hsCRP), IL6, Magnesium, PTH, Calcium, 
Albumin, Phosphate and Magnesium.  Analysis was performed by the department of 
Clinical Chemistry at The Royal Brompton Hospital except for analysis of 1,25(OH)2 
D which was carried out by the Department of Clinical chemistry at West Park 
Hospital, Epsom. 
 
2.14.1:  25(OH)D  
 
Serum 25(OH)D concentration was measured by radioimmunoassay (RIA) after 
acetonitrile extraction (25-hydroxyvitaminD RIA; Immunodiagnostic Systems, 
Boldon, Tyne and Wear).  Sodium hydroxide solution (1%) and acetonitrile were 
added to samples which caused precipitation of serum proteins.  Following 
centrifugation, portions of the supernatant were incubated with 125I-labelled 25-OHD 
and a highly-specific sheep antibody to 25-OHD.  Separation of antibody-bound 
tracer from free was achieved by a short incubation with Sac-Cel® (antisheep IgG 
cellulose) followed by centrifugation and decanting. Bound radioactivity was 
inversely proportional to the concentration of 25-OH D.  
 
This assay measures 25(OH)D3 and has a 75% cross reactivity with 25(OH)D2.  It 
correlates well with measurements made by high performance liquid chromatography 
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(r
2 
= 0.89) and the other available RIA, Diasorin (r
2 
= 0.92) (Zerwekh 2004).  
However it can underestimate the total quantity of serum 25(OH)D because it does 
not react quantitively with 25(OH)D2  (Hollis 2000). 
 
2.14.2:  1,25(OH)2D 
 
Serum 1,25(OH)2D was measured by enzyme immunoassay (EIA) after 
immunoextraction (1,25-DihydroxyVitaminD EIA; Immunodiagnostic systems, 
Boldon, Tyne and Wear). 
 
Patient samples were delipidated and 1,25(OH)2D extracted from potential cross-
reactants by incubation for 90 minutes with a highly specific solid phase monoclonal 
anti-1,25(OH)2D. The immunoextraction gel was then washed and purified 
1,25(OH)2D eluted directly into glass assay tubes. Reconstituted eluates and 
calibrators were incubated overnight with a highly specific sheep anti-1,25(OH)2D.  A 
portion of this was then incubated for 90 minutes whilst shaking in microplate wells 
coated with a specific anti-sheep antibody. 1,25(OH)2D linked to biotin was then 
added and the plate shaken for a further 60 minutes before aspiration and washing. 
Enzyme (horseradish peroxidase) labelled avidin was added which binds selectively 
to complexed biotin and, following a further wash step, colour was developed using a 
chromogenic substrate (TMB). The absorbance of the stopped reaction mixtures were 
read in a microtitre plate reader, colour intensity developed being inversely 
proportional to the concentration of 1,25(OH)2D.   
 
This sensitivity of this assay (defined as the concentration corresponding to the mean 
 71 
minus 2 standard deviations of 20 replicates of the zero calibrator) is 6 pmol/L  The 
specificity for 1,25(OH)2D and its metabolites is shown in table 2.1. 
 
Table 2.1:  Specificity of 1,25(OH)2D RIA, IDS, Tyne and Wear 
 
Analyte Cross-reactivity 
1,25-Dihydroxyvitamin D3 100% 
1,25-Dihydroxyvitamin D2 39% 
24,25-Dihydroxyvitamin D3 0.056% 
25-Hydroxyvitamin D3 0.009 % 
 
 
In view of the lack of cross-reactivity with 1,25(OH)2D2, this assay can again 
underestimate the total serum 1,25(OH)2D.  Because of its presence in extremely low 
concentrations in the serum combined with the presence of other interfering 
substances and low ionising properties, techniques for measuring serum 1,25(OH)2D 
concentration have been more difficult to develop than those for measuring serum 
25(OH)D concentration.  However in recent years, purification prodedures and liquid 
chromatography techniques have been developed (van den Ouweland, Vogeser et al. 
2013) 
 
2.14.3:  PTH, albumin, electrolytes and inflammatory markers 
 
 
Calcium, phosphate, albumin and hsCRP were all run on the Beckman DxC600 
autoanalyser., and PTH and IL6 were run on the Beckman Access 2 Immunoassay 
 72 
analyser (Beckman Coulter, High Wycombe, UK) according to the manufacturers 
instructions. 
 
2.15:  Genotype Analysis 
 
For genotype analysis, a 5ml EDTA blood sample was taken. Samples were frozen 
immediately and stored at –80 degrees centigrade and analysed in a batch by Dr 
James Skipworth at The Department of Cardiovascular Genetics, Rayne Institute, 
University College, London.   DNA was extracted by salting out.  The ACE I/D and 
Bradykinin +9/-9 polymorphisms were run on a Microplate array diagonal gel 
electrophoresis (MADGE) gel whilst all other polymorphisms were genotyped using 
TaqMan  (table 2.1). 
 
Table 2.2:  Genetic polymorphisms 
 
  
Gene Name rs number DNA change AA change 
ATR1 A1166C rs5186 A→C - 
AGT Met235Thr rs699 C→T Met→Thre 
ACE I/D rs4646994  Alu repeat 
GC  rs7041 G→T Asp→Glut 
GC  rs4588 C→A Thre→Lys 
CYP2R1  rs10741657 C→A  
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2.15.1:  DNA whole blood extraction and quantification 
 
DNA extraction was carried out using the Miller et al. ‘salting-out’ method outlined 
in A simple salting out procedure for extracting DNA from human nucleated cells 
(Miller, Dykes et al. 1988). This included a whole-blood cellular lysis step using 
‘reagent A’ and centrifugation at 10,000rpm for 10min, which was repeated once, 
followed by a nuclear lysis step using ‘reagent B’. The pellets were resuspended 
following each centrifugation. 5M sodium per chlorate was added to the lysed nuclear 
pellets the tubes were left to shake for 20min. Chloroform was then added and the 
tubes were centrifuged at 3000rpm for 3min. The aqueous phase was transferred to a 
clean tube for precipitation with -20°C 100% ethanol. The woolly DNA was 
collected, washed with 70% ethanol and stored at room temperature in TE buffer for 2 
weeks to allow the viscous DNA to dissolve 
 
2.15.2:  DNA Extraction Reagents 
 
Reagent A (Cellular Lysis): 
0.32M  Sucrose  109.54g 
5mM  MgCl2   5ml of 1M solution 
10mM  Tris-HCl pH7.5  10mlof 1M solution 
1%  Triton-X-100  10ml 
Made up to 1L with deionised water and stored at 4°C (discarded after 3 weeks) 
 
Reagent B (Nuclear Lysis): 
10mM Tris-HCl p8.2  10ml of 1M solution 
0.4M NaCl   23.4g 
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2mM Na2EDTA pH8.0 4ml of 0.5M solution  
Made up to 900ml with deionised water and autoclaved. After autoclaving 100ml 
10% SDS was added. Stored at room temperature 
 
TE Buffer: 
10mM Tris  1.21g 
1mM EDTA  0.37g 
Make up to 1L with deionised water pH with concentrated HCl. Autoclaved 
 
2.15.3:  DNA quantification and robot standardisation of DNA arrays 
 
Following extraction, DNA concentration of the samples were measured and 
standardised using a Nanodrop® 8000 spectrophotometer and Beckman Coulter 
Biomek® 2000 respectively, to a concentration of 15ng/µl as stock in 96-well array 
plates. These stocks were further diluted to 5ng/µl working stocks which were used to 
run ACE-SNP MADGE gels. 60μl of 1.25ng/μl DNA stocks were made up for the 
8x384-well plates, by using the Beckman Coulter Biomek® 2000 again, to make up a 
5ng DNA weight per sample for the running of the TaqMan assays. 
 
2.15.4:  TaqMan SNP genotyping 
 
Genotyping of the DNA samples was carried out using TaqMan® SNP genotyping 
assay kits which were custom prepared to include TaqMan® Universal PCR Master 
Mix and SNP genotyping mix (containing two polymorphism-specific probes labelled 
with VIC® and FAM™ dyes to detect two forms of the alleles and sequence-specific 
primers surrounding the region of interest). 2μl of the reaction mix was pipetted into 
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each well of the 384-well plates. The polymerase chain reaction (PCR) process was 
conditioned to carry out an initial 10min polymerase activation step at 95°C followed 
by 40 thermal amplification cycles involving a 15sec denaturing step at 92°C and 
1min at 60°C to allow the DNA to anneal and extend. The allele-specific annealing 
probes containing the flourophores are associated with quenchers. On release during 
PCR (at the base-by-base displacement/elongation stage), the fluorophores fluoresces 
depending on which were initially bound. The Applied Biosystems™ 7900HT Fast 
Real-Time PCR System was used to detect optical densities at the two wavelengths 
and allelic discrimination data was derived indicating the allele(s) present in each 
sample. Since testing for these single nucleotide polymorphisms (SNPs) is well 
established in other studies, the primers did not have to be custom-designed and could 
be ordered directly. Each 384 well TaqMan assay plate contained at least 4 wells 
which served as negative controls eliminating the possibility of false positive results. 
These wells contained H2O and were called NTCs (no template controls). 
 
2.15.5:  MADGE gel ACE I/D genotyping 
 
MADGE was used to identify the ACE allelic composition of the DNA.  ACE 
insertion/deletion polymorphisms were amplified by PCR and identified through 
DNA size differences using 7.5% MADGE. The PCR was run with three primers, to 
prevent mistyping (Shanmugam, Sell et al. 1993), giving products of 65bp and 85bp 
in length corresponding to the insertion (I) and deletion (D) alleles respectively. 
Genotype determination was based on the presence of one or both of these bands, 
representing the homozygotes (DD/II) – clearly differentiated by distance of 
migration – or the heterozygotes (DI) – where two bands were visible. The PCR 
conditions under which the 96-well plates were run involved an initial 5 min at 95°C 
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followed by a 35-repition cycle of 45sec at 95°C, 45sec at 54°C and 30sec at 72°C 
with a final 5min at 72°C step. The 96-well plates were covered with a 20μl layer of 
mineral oil to reduce risk of sample evaporation. The gels were run at 110V for 1hr 
10min to produce the clearly separated bands.   
 
2.16:  Muscle Biopsy 
 
Muscle biopsy samples were taken from the vastus lateralis of the dominant leg.  
Informed consent was obtained.  Local anaesthetic was infiltrated and a 1cm incision 
was made in the skin.  A Bergstrom needle was then used to obtain the muscle 
samples.  Tissue was snap frozen in liquid nitrogen and subsequently stored at -80
o
C 
for later analysis. 
 
2.17:  mRNA Expression 
 
For real-time quantitative polymerase chain reaction (RT-qPCR), RNA was extracted 
from muscle biopsies using trizol (Sigma, UK) as per the manufacturer’s 
recommendations. The concentration of RNA was quantified using a 
spectrophotometer (Nanodrop ND1000, Wilmington, USA). First strand cDNA was 
generated using Superscript
® 
II Reverse Transcriptase (Invitrogen). RT-qPCR analysis 
was carried out in duplicate on each cDNA sample for MHC1, MHCIIa, MHCIIx, the 
myogenic regulatory factors myogenin, mrf4 and myf5, and for the reference 
housekeeping gene human RPLPO (large ribosomal protein), using a 20 μl reaction of 
SYBR
® 
Green Quantitative PCR Kit (Sigma Aldrich, UK) and the primer pair 
(4pmol) in 96 well plates (MicroAmp, Fast optical 96 well reaction plate (0.1 ml) 
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(Applied Biosystems, UK.). The qPCR reactions were run on the 7500 Fast Real-time 
PCR System (Applied Biosystems, UK.), with the following cycle program: 95 ºC for 
10 minutes, then 40 cycles of 95 ºC for 15 seconds, 60°C for 30 seconds, 72°C for 30 
seconds. For each gene studied, the average of the 2 samples for each subject was 
taken and expressed to the power of 2.  This figure was then divided by the result for 
the control gene (RPLPO) and then log transformed to obtain a normal distribution.  
The PCR products were run on a 2% agarose gel to confirm the size of the product.   
 
For myogenin and myf5, the primer sequences as shown in table 2.2 were selected 
based on the work of Plant et al (Plant, Brooks et al. 2010).  For mrf4 the primer 
sequence chosen was used by Mckay et al (McKay, O'Reilly et al. 2008).   
 
Table 2.2: mRNA primer sequences 
 
Gene Forward Reverse  
RPLPO TCTACAACCCTGAAGTGCTTGATATC GCAGACAGACACTGGCAACATT  
MHC1 CCCTGGAGACTTTGTCTCATTAGG AGCTGATGACCAACTTGCGC  
MyHCIIa TCACTTATGACTTTTGTGTGAACCT CAATCTAGCTAAATTCCGCAAGC  
MyHCIIx TGACCTGGGACTCAGCAATG GGAGGAACAATCCAACGTCAA  
myogenin GCTGTATGAGACATCCCCCTACTT CGTAGCCTGGTGGTTCGAA  
mrf4 CCCCTTCAGCTACAGACCCAA CCCCCTGGAATGATCGGAAAC  
myf5 GATGTAGCGGATGGCATTCC AGGTCAACCAGGCTTTCGAA  
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2.18:  VDR Protein Measurement 
 
Muscle samples were powdered, mixed with NP40 to extract protein and 
homogenised at 3000 RPM for 1 min.  The supernatant was transferred into a fresh 
tube, diluted and quantified using the Bradford method (Bradford 1976): 
 
Protein samples were diluted to a concentration of 1 in 50.  90μl of Bradfords solution 
which contains coomassie brilliant blue was added to 10μl of each sample and 
incubated for 30 mins.  Bovine serum albumin (BSA) was used to generate a standard 
curve.  Absorbance was then measured at 595nm and the protein concentration of 
samples were calculated using the following equation: emission-intercept / gradient.  
The samples were then diluted to give a 1mg/ml concentration of protein. 
 
100μg of protein samples were loaded onto a 4-20% SDS PAGE gel.  Proteins were 
separated and transferred onto a nitrocellulose membrane.  The blot was incubated 
with 5% bovine serum albumin (BSA) in Tris-HCl buffered saline solution containing 
0.1% Tween 20 (TBS-T) for 1 hour at room temperature and then with the primary 
VDR antibody solution (D6 monoclonal; Insight Biotech Ltd, 0.2 μg/ml) overnight.  
The blot was washed with PBS-Tween on a rocker for 3 lots of 10 minutes before the 
secondary antibody was added (rabbit antimouse) and incubated for a further 1 hour.  
ECL reagent was then added before exposure to kodak film. 
 
The VDR D6 antibody was chosen as it has been shown to be more specific and 
sensitive than a number of other VDR antibodies (Wang, Becklund et al. 2010).  
100μg protein were used based on other studies (Tishkoff, Nibbelink et al. 2008; 
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Wang, Becklund et al. 2010) and our own trials in the laboratory.   
 
 
 
 
 
 
 80 
Chapter 3: Skeletal Muscle Strength and Endurance in 
COPD 
 
3.1:  Introduction 
 
This chapter describes a clinical study comparing serum 25(OH)D and 1,25(OH)2D 
concentrations and properties of skeletal muscle in COPD subjects with an age and 
sex matched control population. 
 
What is known about the role that Vitamin D status plays in healthy older people is 
described in detail in chapter 1.  The limited evidence available has demonstrated that 
COPD patients have a lower serum 25(OH)D concentration and this is in keeping 
with their reduced physical activity and poor nutritional state.   
 
COPD patients have reduced type II muscle fibre diameter as well as a reduction in 
proportion and size of type I muscle fibres.  Vitamin D status appears to 
predominantly affect Type II muscle fibres and hence we would still expect to see a 
link between vitamin D status and skeletal muscle strength in COPD subjects. 
 
Skeletal muscle endurance has also been demonstrated to be reduced in COPD 
patients (Swallow, Gosker et al. 2007). Endurance properties of muscle depend on the 
number and proportion of Type I fibres and hence the findings in COPD patients are 
not surprising.  Studies in VDR knockout mice however show reduction in both Type 
I and Type II fibres so it is possible that Vitamin D status is important for both fibre 
types and may be related to endurance properties in muscle. 
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The aims of this clinical study are as follows: 
 
1)  To establish whether serum 25(OH)D concentrations in a COPD population are 
lower than an age and sex matched control population. 
 
2)  To establish whether there is an independent relationship between serum 25(OH)D 
or 1,25(OH)2D concentrations and both voluntary and involuntary measures of 
skeletal muscle strength in subjects with COPD. 
 
3)  To establish whether serum 25(OH)D or 1,25(OH)2D concentrations are related to 
skeletal muscle endurance in normal or COPD subjects 
 
3.2:  Results 
 
3.2.1:   Subject demographics 
 
104 patients with COPD and 100 control subjects were included in this study.  Patient 
demographics are shown in Table 3.1.  
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Table 3.1:  Demographics of COPD and control subjects in the Study 
 COPD patients 
(n=104) 
Control subjects 
(n=100) 
p value 
 
Age (years) 
Gender (M/F) 
BMI (kg/m
2
) 
FFMI 
smoking pack years* 
daily vitamin D intake* (iu) 
Yale physical activity score 
Yale energy expenditure 
(kcal/week) 
 
65 (56-74) 
60 / 44 
24.1 ± 4.3 
15.8 ± 2.0 
42 (30-60) 
199 (60-906) 
47.7 ± 25.9 
5176 ± 3874 
 
63 (54-72) 
59 / 41 
25.9 ± 4.7 
17.6 ± 3.3 
2 (0-14) 
254 (89-1458) 
70.9 ± 26.4 
7919 ± 4381 
 
0.18 
0.85 
0.04 
<0.001 
<0.001 
0.10 
<0.001 
<0.001 
FEV1 (% predicted) 
FVC (% predicted) 
TLco (% predicted) 
pO2 (KPa) (n=56) 
pCO2 (KPa) (n=56) 
44 ± 22 
85 ± 22 
39 ± 16 
9.4 ± 1.4 
5.2 ± 0.7 
102 ± 16 
105 ± 17 
- 
- 
- 
<0.001 
<0.001 
Values are expressed as numbers for categorical variables and mean ± standard deviation for normally 
distributed continuous variables.  For variables that were not normally distributed, values are shown as 
median (range) (indicated by *). 
 
 The groups are well matched for age and sex but COPD patients had a lower BMI 
and fat free mass, as well as reporting lower levels of physical activity.  Vitamin D 
intake was similar in both groups.  The pattern of Vitamin D supplementation was 
slightly different between groups: more COPD subjects were taking prescribed D3 
supplements than controls, whilst more control subjects were taking fish oil 
supplements or a combination of supplements (figure 3.1). A similar proportion of 
subjects (just under 50%) in both groups were not taking any vitamin D 
supplementation. 
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Figure 3.1: Pattern of Vitamin D supplementation in COPD and control 
Groups
 
 
 
15 patients had GOLD stage 1 disease, 18 GOLD stage 2, 39 GOLD stage 3, and 32 
GOLD stage 4 (figure 3.2). 
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Figure 3.2:  Distribution of COPD severity in study participants 
 
 
 
 
The median ADD of prednisone, consumed mostly as short burst treatment for 
exacerbations, was 2mg.  Seven patients were taking regular low dose (<10mg/day) 
oral prednisolone.  27% of patients had no exacerbations in the preceding year, 22% 
had 1, 14% had 2, 11% had 3 and 26% had 4 or more exacerbations. 
 
3.2.2:  Serum measurements 
 
Serum 25(OH)D and 1,25(OH)2D concentrations did not differ significantly between 
groups, but serum PTH levels were higher in the COPD group, and the ratio of serum 
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25(OH)D concentration to serum PTH concentration was significantly lower in the 
COPD group. 
 
No significant difference was seen between serum calcium, phosphate, magnesium or 
albumin levels between groups.  Serum markers of inflammation (IL6 and hs CRP) 
were significantly higher in the COPD group (table 3.2). 
 
Table 3.2:  Comparison of serum Vitamin D metabolites, Ca
2+
, Po
4-, 
Mg
2+
,
 
PTH 
and inflammatory markers between COPD and control groups. 
 
Serum measurements 
 
COPD patients 
(n=104) 
Control subjects 
(n=100) 
p value 
 
25(OH)D (nmol/l) 
1,25(OH)2D (pmol/l) 
PTH (pmol/ml) 
25(OH)D/PTH* 
Adjusted Ca
2+
 (mmol/l) 
Phosphate (mmol/l) 
Magnesium (mmol/l) 
Albumin (g/l) 
hsCRP (mg/l)* 
IL6 (pg/ml)* 
 
48.5 ± 25.5 
81.2 ± 32.4 
5.2 ± 2.3 
9.1 (68.4) 
2.4 ± 0.1 
1.1 ± 0.2 
0.9 ± 0.8 (n=52) 
37.6 ± 5.7 
0.30 (761.0) 
2.05 (20.9) 
 
55.4 ± 28.3 
82.1 ± 30.1 
4.4 ± 2.0 
12.4 (103.8) 
2.4 ± 0.1 
1.1 ± 0.2 
0.9 ± 0.7 (n=52) 
39.0 ± 5.1 
0.08 (362.0) 
1.18 (26.9) 
 
0.07 
0.82 
0.01 
0.008 
0.10 
0.27 
0.79 
0.06 
<0.001 
<0.001 
Values are expressed as numbers for categorical variables and mean ± standard deviation for normally 
distributed continuous variables.  For variables that were not normally distributed, values are shown as 
median (range) (indicated by *). 
 
3.2.3:  Factors affecting serum 25(OH)D concentration 
 
In a stepwise multivariate regression model involving all study subjects, ethnicity, age 
and daily vitamin D intake were independently associated with serum 25(OH)D 
concentration (r
2
=0.11).  Other factors not retained in the model were study group, 
number of pack years, sex, BMI, time of year measured, albumin, IL6 or hsCRP.   
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A separate analysis of those subjects not taking vitamin D supplements showed a 
significantly lower dietary Vitamin D intake in COPD compared to control subjects 
(982iu ± 611 in COPD vs. 1287iu ± 658 in controls, p=0.01), and significantly lower  
serum 25(OH)D concentration (COPD 41.5nmol/l ± 24.6; Controls 54.8nmol/l ± 32.9, 
p=0.03).     
 
Analysis of serum 25(OH)D concentration according to the time of year measured 
showed a different pattern in the COPD and control groups.  Whilst levels in subjects 
measured between November and February were similar in both groups (COPD: 44.6 
(26.5)nmol/l; Control: 44.6 (23.5) nmol/l), levels in subjects measured between March 
and October were significantly higher in the control group but not in the patients 
(COPD 50.2 (25.0) nmol/l, mean difference -5.6[-16.5-5.2]; Control: 58.8 (29.0) 
nmol/l, mean difference -14.2 [-27.2--1.2]) (figure 3.3). 
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Figure 3.3:  Variation in 25(OH)D level in COPD and control groups according 
to time of year measured. 
 
* mean difference -5.6[-16.5 – 5.2], p=0.31, † mean difference -14.2[-27.2 - -1.2], 
p=0.03 
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3.2.4:  Muscle strength 
 
A significant difference was seen between QMVC, handgrip strength and SNiP 
measurements between groups but not in TwQu (table3.3).  Only 71 COPD subjects 
and 68 control subjects were able to tolerate the protocol for TwQu measurement due 
to discomfort. 
 
Table 3.3:  Comparison of muscle strength measurements between COPD and 
control groups. 
 COPD patients 
(n=104) 
Control subjects 
(n=100) 
p value 
Muscle measurements 
QMVC (kg) 
TwQu (kg) 
Handgrip (kg) 
SNiP (cmH2O) 
 
29.3 ± 12.5 
8.5 ± 3.4 (n=71) 
32.7 ± 11.0 
64.0 ± 20.0 
 
41.2 ± 13.9 
9.5 ± 3.1 (n=68) 
36.5 ± 10.6 
80.5 ± 24.0 
 
<0.001 
0.09 
0.02 
<0.001 
Values are expressed as numbers for categorical variables and mean ± standard deviation for normally 
distributed continuous variables.  For variables that were not normally distributed, values are shown as 
median (range) (indicated by *). 
 
In the COPD patients, neither serum 25(OH)D nor serum 1,25(OH)2D concentration 
were associated with any measure of muscle strength (25(OH)D and QMVC: 0.005[-
0.17-0.19], p=0.96; 25(OH)D and handgrip: 0.03[-0.16-0.21], p= 0.75; 25(OH)D and 
TwQu: -0.1[-0.34-0.15], p=5.22; 25(OH)D and SNiP: 0.04[-0.22-0.25], p=0.79; 
1,25(OH)2D and QMVC: -0.04[-0.25-0.18, p=0.73; 1,25(OH)2D and handgrip: -0.07[-
0.28-0.14], p=0.56; 1,25(OH)2D and TxQu: -0.10[-0.34-0.15], p=0.52; 1,25(OH)2D 
and SNiP: -0.07[-0.33-0.22], p=0.66) (figure 3.4) either independently or in stepwise 
analysis including potential confounding factors.  QMVC was independently 
associated with sex, TLco (carbon monoxide transfer) (%pred) and albumin. 
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Dominant hand grip strength was associated with sex and age. SNiP was associated 
with sex and RV/TLC (residual volume / total lung capacity) (table 3.4). 
Figure 3.4:  Correlations between 1,25(OH)2D and measures of muscle strength 
in the COPD and control groups. 
 
A QMVC: COPD r=-0.04, p=0.73; Control r=0.2, p=0.05; B  TwQu: COPD r=-0.04, p=0.76; Control 
r=0.30, p=0.01; C  Handgrip strength: COPD r=-0.08, p=0.44; Control r=0.31, p=0.003; D SNiP: 
COPD r=-0.01, p=0.91; Control r=0.28, p=0.01 
 
In the control group, serum 25(OH)D concentration was significantly associated with 
TwQu (r=0.29[-0.02-0.48], p=0.02,), SNiP (r=0.22-0.27-0.43], p=0.04) and handgrip 
strength (r=0.20[0.07-0.38], p=0.05), but not with QMVC (r=0.18, p=0.07).  |Serum 
1,25(OH)2D concentration was associated with QMVC (r=0.20[0.002-0.39], p=0.05), 
TwQu (r=0.29[0.07-0.49], p=0.03), SNiP (r=0.28[0.04-0.50], p=0.03) and handgrip 
(r=0.31[0.12-0.49], p=0.003) (figure 3.4).   
 
A C 
B D 
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Univariate analysis was carried out for individual factors thought to affect skeletal 
muscle strength, the results of which are shown in Table 3.4. 
 
Table 3.4: Results of univariate analysis of individual factors and their 
association with QMVC(kg) in COPD and Control populations 
 COPD Control 
Age -0.24 [-0.5 – 0.03]) 
p=0.07 
-0.60 [-0.89 - -0.31] 
p=0.00 
Sex -16.61 [-20.34 - -12.88] 
p=0.00 
-17.45 [-21.87 - -13.03] 
p=0.00 
FFMI 3.6 [2.62 – 4.58] 
p=0.00 
2.82 [ 2.18 – 3.46] 
p=0.00 
Yale physical 
activity score 
0.06 [-0.07 – 0.10] 
p=0.19 
0.15 [0.05 – 0.25] 
p=0.005 
FEV1 (% pred) 0.14 [0.03 – 0.25] 
p=0.02 
-0.09 [-0.26 – 0.08] 
p=0.29 
exacerbation rate -1.68 [-3.26 - -0.11] 
p=0.04 
N/A 
1,25(OH)2D 
(nmol’l) 
-0.01 [-0.09 – 0.07] 
p=0.73 
0.09 [-0.001 – 0.18] 
p=0.05 
Log IL6 -0.98 [-7.09 – 5.13] 
p=0.73 
0.48 [-5.58 – 6.55] 
p=0.87 
Albumin (g/l) 0.59 [0.17 – 1.02] 
p=0.007 
0.41 [-0.13 – 0.95] 
p=0.13 
 Values shown are B [95% CI)] N/A = not applicable 
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Factors that were significant in the above univariate analysis were then included in a 
stepwise multivariate regression model.  For COPD therefore, this model included 
sex, FFMI, FEV1(% pred), exacerbation rate and albumin.  Factors that remained 
significant in stepwise multivariate regression were sex, FEV1(%pred) and Albumin 
(Table 3.5) 
 
 
Table 3.5: Factors which remained associated with QMVC after stepwise 
multivariate analysis in COPD patients. 
 B [95% confidence 
interval] 
p value 
sex -15.94 [-14.49 - -12.29] p = 0.00 
FEV1(% pred) 0.15 [0.11 – 0.74] p = 0.001 
Albumin (g/l) 0.42 [0.11 – 0.74] p = 0.009 
Factors which did not remain significant in the model were FFMI and exacerbation rate. 
 
For the Control group the model included age, sex, FFMI, YPA score, and 
1,25(OH)2D.  When included in a multivariate regression model, factors which 
remained significant were FFMI, YPA score, Age and sex (table 3.6) 
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Table 3.6: Factors which remained associated with QMVC after stepwise 
multivariate analysis in control subjects. 
 B [95% confidence 
interval] 
p value 
FFMI 1.32 [0.36 – 2.28] p = 0.008 
YPA score 0.10 [0.03 – 0.18] p = 0.008 
Age -0.39 [-0.07 - -0.14] p = 0.003 
Sex -8.91 [ -15.02 - -2.8] p = 0.005 
Factors which did not remain significant in the model were 1,25(OH)2D. 
 
When the same analysis was carried out in normal subjects for handgrip strength 
rather than QMVC, 1,25(OH)2D remained significant in the model, rather than YPA 
score (table 3.7) 
 
Table 3.7: Factors which remained associated with handgrip strength after 
stepwise multivariate analysis in control subjects. 
 
 B [95% confidence 
interval] 
p value 
FFMI 0.90 [0.26 – 1.55] p = 0.007 
1,25(OH)2D 0.07 [0.02 – 0.11] p = 0.003 
Age -0.34 [-0.52 - -0.17] p = 0.000 
Sex -8.43 [-12.57 - -4.29] p = 0.000 
Factors which did not remain significant in the model were YPA score. 
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An interaction analysis was performed which showed an independent effect of COPD 
on QMVC (F=20.63, p=0.00) and of having serum 25(OH)D of less than 30nmol/l 
(F=8.05, p=0.000) but no combined effect of COPD and low 25(OH)D. 
 
3.2.5:  Quadriceps endurance 
 
Quadriceps endurance was measured in 35 subjects in each group.  A significant 
difference in force decay was seen between COPD and control groups (Z=6.7% 
[95%CI: 2.1%-11.3%], p=0.004) (figure 3.5).  No difference was seen in force decay 
between vitamin D insufficient and vitamin D sufficient subjects in either study 
group. 
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Figure 3.5:  The comparison between force decline during the endurance 
protocol in COPD patients (circles) and control subjects (triangles).  
 B=6.5 [95%CI 1.9-11.1], p=0.006.  Error bars represent the standard error of the mean. 
 
 
3.2.6:  Serum 25(OH)D and 1,25(OH)2D concentration and lung function 
 
In the COPD group, serum 25(OH)D concentration was associated with FVC (%pred) 
(r=0.21, p=0.04) but no other measure of lung function, whilst serum 1,25(OH)2D 
concentration was not associated with any measures of lung function. After stepwise 
multivariate analysis, number of exacerbations per year, pack years and weight 
remained independently associated with FEV1 (%pred) (r
2
 = 0.32), whilst number of 
pack years was independently associated with FVC (%pred) (r
2
=0.15).  Other factors 
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not retained in the models were daily vitamin D intake, season measured, serum 
25(OH)D, 1,25(OH)2D, PTH or albumin. 
In the control group, serum 25(OH)D concentration was correlated with FEV1 (l) 
(r=0.27, p=0.006) and FVC(l) (r=0.31, p=0.002).  Serum 1,25(OH)2D concentration 
was correlated with FEV1(l) (r=0.41, p<0.001) and FVC(l) (r=0.38, p<0.001) as well 
as FEV1(% pred) (r=0.25, p=0.02). After stepwise multivariate analysis; weight, pack 
years and serum 1,25(OH)2D concentration  remained independently associated with 
FEV1(%pred) (r
2
=0.22), and weight and serum 1,25(OH)2D concentration remained 
independently associated with FVC (%pred) (r
2
=0.22).  Other factors not retained in 
the models were daily vitamin D intake, season measured, serum 25(OH)D, PTH or 
albumin. 
 
3.2.7:  Inflammatory mediators 
 
Serum IL6 and high sensitivity CRP concentrations were both elevated in COPD 
patients compared to controls (table 3.2). There was no correlation between 
inflammatory markers and serum 25(OH)D and 1,25(OH)2D concentrations and no 
relationship between inflammatory markers and any measure of skeletal muscle 
function. 
 
3.3:  Discussion 
 
The main findings of this study are as follows: 
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1) No relationship was demonstrated between either serum 25(OH)D and 
1,25(OH)2D concentrations and measures of muscle strength in subjects with 
COPD although in the control group, serum 1,25(OH)2D concentration was 
independently associated with measures of muscle strength.   
2) Quadriceps endurance was not associated with serum 25(OH)D concentration 
in either study group.  
3) Similar serum 25(OH)D and 1,25(OH)2D concentrations were seen in both 
study groups.  However the serum 25(OH)D/PTH ratio was significantly 
lower in the COPD group 
 
Vitamin D status appears particularly to influence type II fibres and the quadriceps in 
COPD shows an increase in the proportion of type IIa fibres and a reduction in their 
cross-sectional area.  Therefore, the complete lack of association between serum 
25(OH)D and 1,25(OH)2D concentrations and muscle strength in the COPD 
population is unexpected.  Quadriceps endurance was significantly reduced in COPD 
patients, but in contrast to strength, which was associated with serum 25(OH)D in 
control subjects, there was no effect of serume 25(OH)D concentration on endurance 
observed in either group.  This may be because the predominant effect of 1,25(OH)2D 
is on type II fibres although studies in VDR knockout mice suggest otherwise.(Endo, 
Inoue et al. 2003)   
 
Only one cross sectional study has looked at serum 25(OH)D concentration and 
handgrip strength in patients with advanced lung disease referred for lung transplant, 
of whom approximately 50% had COPD. This found no association between the two 
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parameters but in COPD muscle weakness occurs predominantly in the muscles of 
locomotion (Forli, Bjortuft et al. 2009). 
 
The finding that there is no significant difference between serum 25(OH)D 
concentration in the study groups is unexpected as the one published study looking at 
this found otherwise (Janssens, Bouillon et al.).  However in this study we did not 
exclude subjects who were taking Vitamin D supplements which was the case with 
the Belgian study.  A similar proportion of subjects in each group were taking 
supplements although the type of supplementation varied as outlined above.  A 
separate analysis of serum 25(OH)D concentration in those not taking supplements 
did demonstrate a significant difference in 25(OH)D levels in this subgroup.  This is 
consistent with the reduced vitamin D intake demonstrated and probable lack of 
outdoor exposure in the summer months in COPD subjects.  Supporting this 
hypothesis is that the levels of serum 25(OH)D in the normal study population were 
higher in those measured between March and October, but not in COPD subjects.  It 
appears that vitamin D supplementation in COPD subjects is successful in boosting 
serum 25(OH)D levels. 
 
Despite the similar concentration of serum 25(OH)D and serum 1,25(OH)2D in both 
study groups, serum PTH concentration was significantly higher and the 
25(OH)D/PTH ratio significantly lower in COPD patients which was an unexpected 
finding.  PTH maintains serum calcium in the normal range through actions on the 
kidneys, bone and CYP27B1 which metabolises 25(OH)D to 1,25(OH)2D, and is 
tightly regulated by 1,25(OH)2D itself.  A possible explanation for the difference seen 
in serum PTH concentration between the two groups could be the presence of 
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magnesium deficiency, as this can cause a blunted PTH response to low 25(OH)D 
levels (Sahota, Mundey et al. 2006) with subsequent reduced bone turnover. Although 
magnesium is predominantly an intracellular ion, serum concentrations did not differ 
between groups making this unlikely to be a significant factor. 
 
One explanation for this lack of effect of serum 25(OH)D and 1,25(OH)2D 
concentrations in COPD is that it is masked by other processes, or simply that the 
magnitude of effect is small in comparison with other phenotypic modulators of 
muscle strength. However, even when adjusted for factors thought to drive muscle 
atrophy including physical activity level, disease severity and exacerbation rate, there 
was still no relationship observed.  
 
An alternative hypothesis is that there is resistance to the actions of 1,25(OH)2D in 
COPD patients.  Although no significant difference was seen between the serum 
concentrations of 25(OH)D or 1,25(OH)2D in our study groups, serum PTH was 
significantly higher and the 25(OH)D/PTH ratio significantly lower in COPD 
patients.  PTH maintains serum calcium in the normal range through actions on the 
kidneys, bone and 25(OH)D, and is tightly regulated by serum 1,25(OH)2D 
concentration.  PTH levels increase with age. This is thought to reflect decreased 
calcium absorption and it has been hypothesised that postmenopausal women have 
resistance to 1,25(OH)D action in the gut but this has not been confirmed (Ebeling, 
Yergey et al. 1994).  The raised serum PTH concentration in our COPD group 
suggests that there may also be increased resistance to 1,25(OH)2D action in the gut 
with less calcium absorption, despite similar serum levels of 25(OH)D.  This process 
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could drive increased bone resorption and may explain why COPD patients have a 
high risk of osteoporosis.   
 
There are a number of potential mechanisms through which 1,25(OH)2D  resistance 
could occur. 1α-hydroxylase (CYP27B1) converts 25(OH)D to 1,25(OH)2D which 
binds to VDRs present in the target organ.  The VDR then forms a heterodimer with 
retinoic acid receptor before it can bind to DNA and effect a response via gene 
transcription. The VDR is also present in the cytoplasm and has been shown to have 
non-genomic effects. Decreased activity of CYP27B1, or decreased expression or 
inappropriate activity of the VDR could result in resistance.  The levels of 
1,25(OH)2D were similar in both groups which suggests that any mechanism of 
resistance would involve the VDR and its interactions.  Potential influences on the 
vitamin D pathway in skeletal muscle in COPD include the presence of inflammation, 
oxidative stress, reduced capillarity, muscle hypoxia and physical inactivity. Of note, 
no relationship between systemic inflammation and serum 25(OH)D concentration 
(IL6: p=0.82; hsCRP: p=0.78) or between systemic inflammation and QMVC (IL6: 
p=0.14; hsCRP: p=0.74) was seen.   
 
3.3.1:  Study limitations 
 
This is a large cross-sectional study with a well-phenotyped cohort of COPD patients 
and a control group matched for age and sex.  However, as with any cross-sectional 
study, it is only possible to look for significant associations and we are not able to 
establish cause and effect relationships.  The population was predominantly 
Caucasian living in the United Kingdom and results must be applied with caution to 
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other populations. One limitation of the study may be the use of the YPAS as a 
measure of physical activity rather than direct measurement.  This is a recall 
questionnaire and therefore has inherent problems associated with it.  However it is a 
useful tool for comparing populations, it has been validated in older people, the 
physical activity score has been shown to correlate with VO2max, and discriminated 
between patients and controls in the present study (Dipietro, Caspersen et al. 1993).  
In our study, the physical activity score correlated with disease severity in the COPD 
group (r=0.30, p=0.004) 
 
3.3.2: Conclusion 
 
The relationship between serum 25(OH)D and 1,25(OH)2D concentration and skeletal 
muscle strength observed in normal subjects was not present in COPD patients despite 
a similar range of serum 25(OH)D levels. These results are surprising and raise the 
possibility of 1,25(OH)2D resistance in COPD.   
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Chapter 4: Muscle Biopsy Sub-study 
 
 
4.1:   Introduction 
 
This chapter describes the findings on skeletal muscle biopsy of a sub-group of 
patients from the previously described clinical study with the aim of investigating 
potential mechanisms of 1,25(OH)2D action in skeletal muscle. 
 
From the evidence presented in the preceding chapter, 25(OH)D does not appear to 
exert its expected clinical effects on muscle in COPD subjects and may therefore be 
contributing to their skeletal muscle dysfunction.  Therefore we wished to investigate 
what was happening at a molecular level. No power calculation was performed prior 
to this study as only small numbers of patients could potentially be recruited for 
muscle biopsies, and the original main outsome measure had not been investigated in 
COPD subjects previously (VDR protein levels in skeletal muscle). 
 
As discussed previously, muscle biopsy studies looking at the effects of 25(OH)D 
deficiency have shown abnormalities in type II or IIa fibres.  We firstly therefore 
chose to look at fibre type mRNA expression to confirm this relationship in healthy 
elderly subjects and to see if the relationship was maintained in COPD subjects. 
 
As mentioned in chapter 1, 1,25(OH)2D has been shown in vitro to have an effect on 
myogenic regulatory factors and we therefore selected these for investigation in 
skeletal muscle.  The myogenic regulatory factors (MRFs) consist of myoD, 
myogenin, mrf4 and myf5.  They have been extensively studied in embryogenesis and 
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in cell culture models where they have been shown to play an important role in 
skeletal muscle development.  MyoD and myf5 commit stem cells to a myogenic 
lineage whilst myogenin and mrf4 stimulate the transition to multinucleated 
myofibres (Yokoyama and Asahara).  However, less is known of their function in 
adult muscle. Mrf4 expression does persist into adult life, whilst the other MRFs 
decrease shortly after birth and subsequently increase with ageing and in disease 
states (Stewart and Rittweger 2006).  MyoD and myogenin mRNA have been shown 
to increase after resistance exercise training in both young and old people, whilst myf5 
mRNA increased only in the young (Kosek, Kim et al. 2006). 
 
A potential mechanism for vitamin D resistance could involve the VDR.  This has 
previously been demonstrated to be present in skeletal muscle (Bischoff, Borchers et 
al. 2001) and has been shown to be reduced in skeletal muscle with increasing age 
(Bischoff-Ferrari, Borchers et al. 2004).  Investigations into the VDR in the 
duodenum have also shown an age related decrease in quantity (Ebeling, Sandgren et 
al. 1992).  As discussed in chapter one, COPD shows some evidence of an accelerated 
ageing process, and if a reduced VDR concentration in skeletal muscle was shown in 
COPD subjects, compared to age and sex matched healthy controls, this may help to 
explain some of the muscle fibre changes seen in this disease 
 
In summary, muscle fibre type and distribution is altered in COPD subjects with a 
shift from Type I to type IIa fibres and subsequent reduction in type IIa fibre size, the 
mechanism for which is not clear.  Serum 25(OH)D has been shown to be related to a 
reduction in size of Type IIa muscle fibres on muscle biopsy and supplementation 
with vitamin D increases the size of Type IIa fibres (Sato, Iwamoto et al. 2005), 
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whilst VDRKO mice studies as well as cell studies support a role for 1,25(OH)2D in 
muscle growth and differentiation via actions on myogenic regulatory factors (Endo, 
Inoue et al. 2003; Garcia, King et al. 2011; Girgis, Clifton-Bligh et al. 2014).  
25(OH)D may therefore effect muscle fibre type through actions on the myogenic 
regulatory factors.  
 
The aims of this study are as follows: 
 
1)  To confirm a relationship between serum 25(OH)D and 1,25(OH)2D 
concentrations and skeletal muscle MyHCIIa mRNA expression and to look for a 
difference in this relationship between COPD and control subjects. 
 
2)  To establish whether there is a negative association between serum 25(OH)D or 
1,25(OH)2D concentration  and mRNA expression of the myogenic regulatory factors 
mrf 4, myf5 and myogenin in skeletal muscle in either COPD or Control subjects. 
 
3)  To establish whether myogenic regulatory factor mRNA expression is related to 
muscle fibre type expression in skeletal muscle in both COPD and Control subjects as 
a potential mechanism for fibre type alterations in COPD. 
 
4) To compare the amount of VDR present in skeletal muscle in COPD and Control 
subjects 
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4.2:  Results 
 
4.2.1:  Demographic features, muscle strength and serum measurements in the sub-
study Group 
 
26 COPD subjects and 13 control subjects agreed to take part in the muscle biopsy 
sub-study.  Their demographic features were in general similar to those of the original 
study groups, although there are some important differences to highlight (Table 1): 
 
The number of females in the control group were low (n=2) and the gender difference 
between the two groups did reach borderline statistical significance.   
 
The Yale Physical Activity score between the groups did not reach statistical 
significance. 
 
Handgrip strength between the groups did not reach statistical significance although 
other measures of muscle strength did. 
 
There was no significant difference in serum PTH concentration or in the 
25(OH)D/PTH ratio seen between the two groups unlike the total clinical study 
groups. 
 
Serum hsCRP concentration, but not serum IL6 concentration,was higher in the 
COPD study group. 
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In the COPD group, there were 6 subjects with GOLD stage I disease, 7 with GOLD 
Stage II, 9 with GOLD Stage III, and 4 with GOLD Stage IV disease.  
 
Table 4.1: Comparison of demographic features, muscle strength and serum 
measurements between groups in participants of the muscle biopsy sub-study 
 COPD Group Control Group p value 
Age (years) 63 (10) 64 (9) 0.87 
Sex (M/F) 15/11 11/2 0.05 
BMI 23.8 (4.1) 27.9 (5.4) 0.01 
FFMI 16.0 (2.1) 19.6 (3.0) < 0.001 
smoking pack years*
 43.5 (107) 10 (56) <0.001 
Yale Physical Activity Score 52.2 (32.2) 73.9 (34.1) 0.07 
daily vitamin D intake (iu)*
 431 (1773) 1405 (2793) 0.31 
FEV1 (% pred) 52 (26) 98 (8) <0.001 
QMVC (kg) 31.7 (11.7) 43.3 (11.8) 0.006 
TwQu (kg) 8.4 (3.7) 10.7 (2.9) 0.008 
dominant handgrip (kg) 33.5 (11.0) 38.4 (7.0) 0.16 
SNIP (cmH2O) 66.7 (18.9) 88.0 (18.2) 0.004 
25(OH)D (nmol/l) 48.8 (28.9) 60.0 (33.9) 0.30 
1,25(OH)2D (pmol/l) 73.8 (37.4) 88.0 (30.7) 0.25 
PTH (pmol/ml) 5.4 (2.6) 4.1 (2.4) 0.13 
25(OH)D/PTH 48.8 (28.9) 60.0 (33.8) 0.16 
IL6 (pg/ml)*
 1.8 (9.9) 1.0 (2.7) 0.13 
hsCRP (mg/l)*
 0.34 (1.37) 0.06 (0.26) <0.001 
Values are expressed as numbers for categorical variables and mean (standard deviation) for normally 
distributed continuous variables.  For variables that were not normally distributed, values are shown as 
median (range) (indicated by *). 
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4.2.2:  mRNA analysis 
 
MHC1 mRNA expression was lower in the COPD group compared to the control 
group (4.19±0.41 vs 3.88±0.42, p=0.04), whilst expression of MyHCIIa 
(COPD:2.98±0.67, control:2.97±0.43, p=1.00) and MyHCIIx (COPD:3.82±0.59, 
control:3.78±0.52, p=0.82) was similar in both groups.  No difference was seen in 
mRNA expression for any of the MRFs between the COPD and control groups. 
 
Table 4.2:  Comparison of mRNA expression between COPD and control 
Groups 
 COPD Control mean difference p-value 
Log MHCI 3.88 (0.42) 
(n=26) 
4.19 (0.41) 
(n=12) 
-0.31[-0.61 - -0.02] 0.04 
Log MyHCIIa 2.98 (0.67) 
(n=25) 
2.97 (0.43) 
(n=13) 
0.00 [-0.42 – 0.42] 1.0 
Log MyHCIIx 3.82 (0.59) 
(n=25) 
3.78 (0.52) 
(n=12) 
0.04 [-0.36 – 0.45] 0.82 
Log mrf4 3.32 (0.77) 
(n=22) 
3.39 (0.54) 
(n=12) 
0.07 [-0.88 – 0.44] 0.78 
Log myf5 1.5 (0.60) 
(n=21) 
1.5 (0.35) 
(n=9) 
0.98 [-0.44 – 0.43] 0.98 
Log myogenin 2.3 (0.40) 
(n=25) 
2.3 (0.44) 
(n=12) 
0.03 [ -0.26 – 0.33] 0.83 
Values are expressed as mean (standard deviation) and mean difference [95% confidence intervals].  
Values shown are calculated as described in the methods section (chapter 2). 
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In the control group, MyHCIIa was associated with both 25(OH)D (figure 4.1) and 
1,25(OH)2D (r
2
=0.47, p=0.01 and r
2
=0.35, p=0.03 respectively).  In the COPD group, 
no association between MyHCIIa and 25(OH)D ( r
2
=0.00, p=1.0) or 1,25(OH)2D 
(r
2
=0.08, p=0.20) was seen..   
 
No association was seen between mRNA expression of MRFs and either serum 
25(OH)D concentration in the COPD group (mrf4: r
2
=0.16, p=0.62; myf5: r
2
=0.16, 
p=0.08, myogenin: r
2
=0.01, p=0.72). In the control group, there was a trend for an 
association between 25(OH)D and the mrfs as follows: myf 5 (r
2
=0.38, p=0.08); mrf 4 
(r
2
=0.32, p=0.06); myogenin (r
2
=0.30, p=0.07).  
Table 4.3:  Correlations between serum 25(OH)D concentration and mRNA fibre 
type expression, and mRNA expression of myogenic regulatory factors between 
groups. 
  MHCI MyHCIIa MyHCIIx mrf4 myf5 myogenin 
COPD 25(OH)D  r
2
=0.04 
p=0.35 
r
2
=0.00 
p=1.0 
r
2
=0.02 
p=0.57 
r
2
=0.001 
p=0.88 
r2=0.16 
p=0.08 
r
2
=0.01 
p=0.72 
Control 25(OH)D r
2
=0.22 
p=0.13 
r
2
=0.47 
p=0.01 
r
2
= 0.22 
 p=0.13 
r
2
=-0.32 
p=0.06 
r
2
=-0.38 
p=0.08 
r
2
=0.30 
p=0.07 
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Figure 4.1:  Correlation between serum 25(OH)D concentration and MyHCIIa 
mRNA expression in COPD and Control Groups 
 
COPD: r
2
=0.00, p=1.0; Control: r
2
=0.47, p=0.01 
 
In the control group a number of associations were found between MRFs and fibre 
type mRNA expression: mrf4 was most strongly associated with MyHCIIa (r
2
=0.52, 
p=0.009) (figure 4.2) whilst myf5 was most strongly associated with MHCI (r
2
=0.72, 
p=0.004) (figure 4.3).  In the COPD group, an association was found between mrf4 
and MyHCIIa (r
2
=0.4x, p=0.02) (figure 4.2), and MyHCIIx (r
2
=0.34, p=0.005), but not 
with MyHCIIa and myf5 (r
2
=0.009, p=0.68) (figure 4.2) or myogenin (Tables 4,5&6). 
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Table 4.4:  Correlations for mrf4 mRNA and fibre type mRNA expression 
  MHC1 MyHCIIa MyHCIIx 
COPD mrf4 r
2
=0.07, 
p=0.24 
r
2
=0.40, 
p=0.02 
r
2
=0.34, 
p=0.005 
Control mrf4 r
2
=0.48, 
p=0.02 
r
2
=0.52, 
p=0.009 
r
2
=0.11, 
p=0.32 
 
Figure 4.2:  Graph showing association between mrf4 and MyHCIIa mRNA 
expression 
 
COPD: r
2
=0.40, p=0.02; Control: r
2
=0.52, p=0.009 
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Table 4.5:  Correlations between myf5 and fibre type mRNA expression. 
  MHCI MyHCIIa MyHCIIx 
COPD myf 5 r
2
=0.009, 
p=0.68 
r
2
=0.05, 
p=0.33 
r
2
=0.05, 
p=0.32 
Control myf 5 r
2
=0.72, 
p=0.004 
r
2
=0.55, 
p=0.02 
r
2
=0.41, 
p=0.07 
 
Figure 4.3:  Graph showing correlation between myf 5 and MHCI mRNA 
expression 
 
COPD: r
2
=0.009, p=0.68; Control: r
2
=0.72, p=0.004 
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Table 4.6:  Correlations between myogenin and fibre type mRNA expression. 
  MHCI MyHCIIa MyHCIIx 
COPD myogenin r
2
=0.04, 
p=0.33 
r
2
=0.13, 
p=0.08 
r
2
=0.15, 
p=0.07 
Control myogenin r
2
=0.35, 
p=0.06 
r
2
=0.27, 
p=0.08 
r
2
=0.02, 
p=0.72 
 
As in the main study group, an association between serum 25(OH)D concentration 
and muscle strength in control subjects was confirmed in this subset of patients 
(COPD: r
2
=0.07,p=0.22, control: r
2
=0.40,p=0.02 for handgrip strength).  As expected, 
MyHCIIa expression (but not MHC1 or MyHCIIa expression) was associated with 
quadriceps strength in normal, but not COPD, subjects (COPD: r
2
 =0.03, p=0.45; 
control: r
2
 = 0.36, p=0.03). 
 
4.2.3: VDR Protein measurements 
 
Despite running a number of western blots with varied protein concentrations and 
varied exposure times, we were unable to achieve a meaningful result for the VDR 
from which the amount of VDR receptor present could be quantified.  A typical 
example of this is shown in figure 4.4. 
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Figure 4.4:  Result of western blot for VDR after incubation with primary (VDR 
D6) and secondary (mouse ISF1) antidodies, and subsequent exposure for 30 
mins after addition of ECL 
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Gel 1 from left to right: ladder; (subject identification)VDAS; KW03; GS06; VW09; HD11; 
CH36; FH02; VDSB.  Gel 2: ladder; VDAS; VDDH; KVB; DK17; PS05; GM21; ACESB; 
VDGH; VDYL.  Superimposed red markings and numbers represent the ladder showing 
50kDa and 75 kDa.  Faint bands show for individual subjects just above the 50kDa mark 
which are assumed to represent the VDR (54kDa)  
 
 
 
4.3:  Discussion 
 
 
The main findings of this sub study are as follows: 
 
1) There was a significant association between serum 25(OH)D 
concentration and MyHCIIa mRNA expression in the control group ,but 
not the COPD group. 
2) A significant association was also seen between serum 25(OH)D 
concentration and mr4 mRNA expression in the control, but not the 
COPD group. 
3) A significant strong correlation was found between mrf4 and MyHCIIa 
mRNA expression and between myf5 and MHCI mRNA expression again 
in the control, but not the COPD group. 
 
These results are consistent with the findings in the clinical study in that both clinical 
associations and those associations seen at a molecular level in healthy elderly 
subjects do not appear to be present in those with COPD.  However numbers in this 
study are small and it may be underpowered in order to detect associations in COPD.  
The signalling pathways of 25(OH)D and 1,25(OH)2D   in muscle are complex and 
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not completely understood and evidence that is available is outlined in chapter 1.  The 
results of this study would suggest that they may influence muscle fibre type and or 
growth through actions on the myogenic regulatory factors, in particular mrf4.  
 
Endo et al showed persistent up regulation of myf5, myogenin and early MHC 
isoforms in the skeletal muscle of VDRKO mice (Endo, Inoue et al. 2003).  Addition 
of 1,25(OH)2D to  muscle cells in vitro showed down regulation of these factors.  
Tsuji et al demonstrated in an osteoblast cell line that 1,25(OH)2D enhanced the 
expression of 1mfa, a known inhibitor of myogenic regulatory factors (Tsuji, Kraut et 
al. 2001).  A further study in C2C12 myocytes demonstrated increased expression of 
the VDR with increased translocation to the nucleus, decreased expression of markers 
of cell proliferation, and promotion of myocytes differentiation with increased IGF1 
and follistatin, and decreased myostatin expression, all with the addition of 
1,25(OH)2D (Garcia, King et al. 2011).  They also showed variation in expression of 
mrfs at different time points after addition of 1,25(OH)2D. 
 
In our study we found a negative relationship between serum 25(OH)D and 
1,25(OH)2D concentrations and MyHCIIa mRNA expression: low serum 25(OH)D 
levels were associated with high mRNA expression of MyHCIIa.  There was also a 
trend towards a negative relationship between serum 25(OH)D concentration and 
mrf4 mRNA expression (R=-0.56, 0=0.06), and myogenin mRNA expression (R=-
0.55, p=0.07).  These findings are consistent with the above studies showing that 
1,25(OH)2D suppresses expression of mrfs and promotes muscle cell differentiation 
rather than proliferation. 
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The strongest associations found in this study were those between certain mrfs and 
MHC mRNA expression in the control group, and this suggests that different mrfs 
may be important in proliferation of different fibre types in adult muscle.  One study 
in adult rats has demonstrated high levels of myogenin mRNA in skeletal muscle that 
predominantly consists of slow fibres with high levels of myoD mRNA in those that 
consist predominantly of fast fibres.  However, levels of mrf4 mRNA did not differ 
between muscles, whilst myf5 mRNA was virtually undetectable (Hughes, Taylor et 
al. 1993).  Our findings are supported by another study looking at promoter/reporter 
gene constructs of mrf4 which has shown a region which promotes mrf4 specifically 
in fast muscle fibres (Pin and Konieczny 2002). 
 
We were not able to quantify the VDR in skeletal muscle in this study.  A faint 
protein band was demonstrated in some subjects with a weight consistant with that of 
the VDR, but this was not enough to enable accurate measurement.  This may have 
been due to technique as I have not previously carried out western blot analysis 
before, although I was supported by scientists in the laboratory proficient in doing 
this.  A number of repeat samples were run by myself with differing protein 
concentrations and differing exposure times with no large difference in results seen.   
 
Alternatively, there may not have been large amounts of the VDR present in these 
muscle samples.  There is some debate currently about the presence or absence of 
VDRs in skeletal muscle and the antibodies used to detect them.  A recent study by 
Wang et al used the same D6 antibody used in this study and could not demonstrate 
the presence of the VDR in either mouse or human muscle extracts (Wang, Becklund 
et al. 2010).  They also studied other commercially available antibodies and found 
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that these antibodies, but not the D6 antibody were positive in samples of VDR 
knockout mice suggesting binding to other proteins occured.  Only one other study on 
human muscle extracts is published demonstrating evidence of VDR in skeletal 
muscle and this used a different antibody (VDR 9A7).  It is therefore possible that the 
VDR is not present in adult skeletal muscle and 1,25(OH)2D may act indirectly on 
skeletal muscle  but further studies are required to investigate this further. 
 
The limitations of this sub-study are that only a small number of subjects were studied 
and the study was not sufficiently powered to detect differences in some of the 
measurements studied.  However, muscle biopsy data is limited because it is an 
invasive technique which people do not often want to undergo.  It is also difficult to 
draw conclusions regarding cause and effect relationships with a cross-sectional study 
design.  Despite this, some strong associations were found which are consistent with 
previous cell studies looking at the mechanisms of 25(OH)D and 1,25(OH)2D  in 
muscle, and this is the first reported study looking at molecular and clinical 
associations in human skeletal muscle in both healthy elderly subjects and COPD 
subjects.   
 
In conclusion, this sub-study shows associations between serum 25(OH)D 
concentration and MHC mRNA expression in healthy elderly subjects which may be 
related to actions on myogenic regulatory factors.  Consistent with the findings of the 
clinical study, these associations were not present in COPD subjects and this lends 
weight to the argument that skeletal muscle in COPD subjects is resistant to the 
actions of 1,25(OH)2D, and this resistance would appear to occur at a molecular level. 
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Chapter 5: Genetic Influences on Muscle Strength and 
Vitamin D in COPD 
 
5.1:  Introduction 
 
Potential genetic influences of the Vitamin D meatabolic pathway include 
polymorphisms in the vitamin D binding protein, the VDR and in genes encoding 
enzymes for the conversion or breakdown of 25(OH)D and 1,25(OH)2D.  The 
influence of certain polymorphisms in the VDR on muscle strength are outlined in 
Chapter 1.   
 
Two variants in the DBP gene (rs7041 and rs4588) have been shown to be related to 
serum 25(OH)D concentrations (McGrath, Saha et al. 2010), and one of these 
(rs7041) has been related to serum 25(OH)D levels in COPD (Janssens, Bouillon et 
al. 2010).  However there are no published studies looking at potential influences of 
these DBP polymorphisms on skeletal muscle strength. 
 
The renin-angiotensin system (RAS) has widely known systemic effects and, like the 
vitamin D pathway, has more recently been shown to have local effects on differing 
organs which include skeletal muscle. 
 
Angiotensin II is produced by the initial conversion of angiotensinogen to angiotensin 
I by the action of renin, and the subsequent conversion of angiotensin I to angiotensin 
II by Angiotensin Converting Enzyme (ACE) (figure 5.1).  Angiotensin II activates 
the ATR1 Receptor which stimulates aldosterone release from the adrenal cortex and 
 118 
noradrenaline release from sympathetic nerve terminals resulting in vasoconstriction 
and sodium reabsorption.  These effects are counteracted by local activation of ATR2 
receptors. ACE also converts bradykinin to inactive fragments.   
 
Figure 5.1: The Renin-angiotensin system 
 
Whilst expression of the ATR1 receptor is widespread, ATR2 receptor expression is 
restricted to the adrenal glands, uterus, ovaries, lung, heart and brain and does not 
appear to be present in skeletal muscle (Malendowicz, Ennezat et al. 2000).  Increased 
angiotensin II levels are associated with weight loss in subjects with cardiovascular 
disease (Anker, Negassa et al. 2003) and ESRF, and ATR1 receptor blockade has 
been shown to prevent cachexia in a rat model of congestive heart failure (Dalla 
Libera, Ravara et al. 2001). 
 
Serum ACE activity has been negatively associated with skeletal muscle strength, 
Angiotensin II appears to exert these effects on skeletal muscle through varying 
pathways which include IGF-1 suppression (Song, Li et al. 2005), stimulation of NF-
κ-B (Russell, Wyke et al. 2006), PPARδ down regulation (Zoll, Monassier et al. 
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2006) and transforming growth factor beta (TGFβ) activation  (Cohn, van Erp et al. 
2007) with a tendency to promote cachexia, muscle protein degradation and 
inflammation.   
 
The ACE gene has a polymorphism which results in the insertion / deletion of a 287 
base pair fragment. The deletion allele results in higher tissue and circulating ACE 
activity with consequent higher angiotensin II and reduced bradykinin levels 
(McCauley, Mastana et al. 2009).  The DD allele has been associated with better 
power performance in healthy subjects (Nazarov, Woods et al. 2001; Woods, 
Hickman et al. 2001) and has been shown to provide a better response to isometric 
muscle training with an increase in quadriceps strength (Montgomery, Clarkson et al. 
1999).  In contrast the I allele appears to be associated with better endurance 
performance (Myerson, Hemingway et al. 1999) and has been associated with an 
increased proportion of Type I fibres in skeletal muscle (Zhang, Tanaka et al. 2003).   
 
In a previous cross-sectional study of COPD subjects and age and sex matched 
controls, COPD subjects who were homozygote for the deletion allele had greater 
quadriceps strength despite a similar FFM (Hopkinson, Nickol et al. 2004).   However 
in this study, no relationship was found in the control subject group. 
 
The mechanism for this effect on skeletal muscle may be due to the increased RAS 
activity and there are other genetic polymorphisms in the angiotensin pathway that 
have been associated with varying RAS activity.  One of these is the ATR1 A1166C 
polymorphism where the C allele has been associated with increased angiotensin II 
activity (Miller, Thai et al. 1999; van Geel, Pinto et al. 2000). 
 120 
 
Although it has not been demonstrated to be associated with increased RAS, the C 
allele of the Angiotensinogen (AGT) Met235Thr polymorphism has been linked with 
muscle function.  It appears to be more frequent in power athletes compared to 
endurance athletes or a control group (OR: 1.681 (1.176-2.401)) (Gomez-Gallego, 
Santiago et al. 2009).  These three polymorphisms in combination (ACE I/D 
polymorphism, ATR1 A1166C and AGT Met235Thr) have been shown to have a 
combined influence on the development of diabetic nephropathy (Ahluwalia, Ahuja et 
al. 2009) which in itself is thought to be linked with RAS activity (St Peter, Odum et 
al.). 
 
The aims of this chapter are to establish whether the ACE I/D polymorphism, the 
AGT Met235Thr polymorphism and the ATR1 A1166C polymorphism are associated 
with QMVC, either individually or in combination, in COPD subjects compared to 
healthy control subjects. 
 
5.2:  Results 
 
5.2.1:  Allele frequencies 
 
Genotype distributions for COPD and Control Groups for all 3 polymorphisms are 
shown in table 5.1.  There was a significant difference in genotype frequencies for the 
ACE I/D polymorphism between the COPD and Control groups (χ2=6.0, p=0.049).  In 
the control group, genotype distribution was similar to that previously reported in the 
UK population consistent with Hardy Weinberg equilibrium {O'Dell, 1995).  
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However, in the COPD group, the DD genotype frequency was higher than expected.  
The allele frequency for each group was as follows:  COPD:  I = 0.41, D = 0.59; 
Control: I = 0.54, D = 0.46. 
 
A significant difference was also seen in the genotype frequencies between COPD 
and control groups for the AGT polymorphism (χ2=6.6, p=0.04).  A higher frequency 
of the T allele was seen in the COPD group (table 5.1). 
     
Table 5.1:  Allele frequencies in COPD and Control Groups 
 
  ACE AGT ATR1 
Control  II ID DD CC CT TT AA AC CC 
number 33 40 25 23 49 25 48 42 7 
frequency 0.34 0.41 0.25 0.24 0.5 0.26 0.49 0.43 0.08 
COPD number 22 39 41 11 49 37 53 40 6 
frequency 0.22 0.38 0.40 0.11 0.50 0.38 0.54 0.40 0.06 
 
 
5.2.2:  ACE I/D polymorphism 
 
Characteristics of COPD subjects according to ACE I/D polymorphism are shown in 
Table 5.2.  There was a significant difference in FEV1 (% pred) between genotypes 
although this was not related to either allele; the lowest FEV1 was seen in the ID 
group.  No difference was seen other parameters measured. 
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Table 5.2:  Characteristics of COPD subjects according to ACE I/D genotype 
 II 
(n=22) 
ID 
(n=49) 
DD 
(n=31) 
  
Age, yr 64.6 (9.4) 66.5 (7.1) 62.6 (10.2)   
BMI, kg/m
2
 24.4 (3.7) 23.6 (3.9) 24.3 (5.0)   
FFM, kg
 
44.8 (9.1) 43.4 (7.7) 45.5 (9.7)   
FEV1 % predicted
* 
42.8 (19.1) 35.9 (15.3) 49.0 (24.3) F=4.2 p=0.02 
25(OH)D, nmol/l 55.6 (26.0) 50.6 (26.1) 42.5 (24.5)   
QMVC, kg
 
28.7 (14.0) 27.5 (11.4) 30.6 (12.6)   
 
 
Characteristics of the control group according to ACE genotype are shown in table 
5.3.  There was a significant difference seen in FFM across genotype with The D 
allele being associated with the highest FFM (table 5.3). QMVC was also higher in 
the DD group but this did not reach significance.   
 
There was a significant difference in serum 25(OH)D concentration between allele 
groups. Those who were homozygote for the deletion allele had the highest serum 
25(OH)D levels whilst those who were homozygote for the insertion allele had the 
lowest serum 25(OH)D levels (I/I: 43.3 ± 24.1; I/D: 56.4 ± 26.0; D/D: 67.8 ± 31.8; 
F=6.0, p=0.004)  (figure 5.2).    
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Table 5.3:  Characteristics of Control subjects according to ACE I/D 
polymorphism genotype 
 II 
(n=33) 
ID 
(n=40) 
DD 
(n=25) 
  
Age, yr 64.4 (8.1) 62.7 (10.0) 62.4 (7.8)   
BMI, kg/m
2
 25.0 (3.7) 25.6 (4.7) 27.7 (5.0)   
FFM, kg
* 
49.7 (13.5) 50.5 (13.2) 58.2 (14.7) F=3.2 p=0.045 
FEV1 % predicted
 
105.6 (17.8) 100.3 (15.1) 97.2 (14.7)   
25(OH)D, nmol/l
* 
43.3 (24.1) 56.4 (26.0) 67.8 (31.8) F=6.0 p=0.004 
QMVC, kg
 
39.3 (13.5) 41.2 (13.1) 44.9 (15.5)   
      
A univariate linear model was used to look for factors influencing muscle strength.  
For COPD subjects the model included the following factors: age; sex; FFM; 
exacerbation rate; daily steroid dose; FEV1 (% pred); YPAS score; serum 25(OH)D 
and ACE genotype.  For control subjects the model did not include exacerbation rate 
or daily steroid dose.  ACE genotype did not remain significant in the model for either 
COPD or control subjects. 
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5.2.3:  ACE I/D polymorphism and serum 25(OH)D concentration 
Figure 5.2:  Serum 25(OH)D concentration according to ACE I/D polymorphism 
genotype in COPD and Control Groups 
 
Serum 25(OH)D concentration (nmol/l): COPD: I/I: 55.6 ±26.0; I/D 50.6 ± 26.1; D/D: 42.5 ± 24.5; 
Control: I/I: 43.3 ± 24.1; I/D: 56.4 ± 26.0; D/D: 67.8 ± 31.8 
 
 
When season measured, daily vitamin D intake and ethnicity were compared between 
genotype groups, a significant difference was seen only in ethnicity (χ2=17.1, p=0.03).  
Distribution of Caucasian subjects was similar between groups but 6 Indian subjects 
were included in the II genotype group.  Stepwise linear regression was performed 
using the same variables as detailed above for COPD subjects.  The ACE I/D 
genotype was the only factor that remained significant in the model (B=12.3, 
p=0.001). 
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5.2.4:  AGT Met235Thr polymorphism 
 
Characteristics according to AGT genotype are shown in tables 5.4 and 5.5 for COPD 
and Control Groups respectively.  In the COPD group, there was a significant 
difference in both FFM and QMVC with CT heterozygote’s having the lowest FFM 
and being weaker, whilst CC homozygotes were strongest with the highest FFM 
(table 5.4).  No difference was seen between genotype for any parameters measured in 
the control group. 
 
Table 5.4:  Characteristics of COPD subjects according to AGT genotype 
 CC 
(n=11) 
CT 
(n=49) 
TT 
(n=37) 
  
Age, yr 62.0 (7.1) 63.9 (9.8) 66.0 (8.6)   
FFM, kg
 
49.7 (10.4) 42.2 (7.4) 46.1 (9.1) F=4.4 p=0.02 
QMVC, kg
 
36.1 (18.5) 26.5 (9.9) 30.8 (12.4) F=3.2 p=0.04 
FEV1, % pred 38.7 (23.0) 41.7 (20.8) 44.6 (20.2)   
25(OH)D, nmol/l 45.6 (31.4) 45.3 (26.8) 53.5 (23.1)   
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Table 5.5:  Characteristics of Control Subjects according to AGT genotype 
 CC 
(n=23) 
CT 
(n=49) 
TT 
(n=25) 
  
Age, yr 61.2 (9.0) 63.0 (9.1) 65.0 (8.0)   
FFM, kg
 
53.9 (15.0) 51.7 (14.3) 52.0 (13.1)   
QMVC, kg
 
42.8 (14.6) 40.5 (15.0) 42.4 (11.4)   
FEV1, % pred 99.3 (16.1) 102.1 (17.1) 100.5 (14.1)   
25(OH)D, nmol/l 58.8 (28.5) 54.7 (23.8) 51.2 (33.2)   
 
A univariate model was used to look for factors influencing muscle strength using the 
same factors as detailed above.  AGT genotype did not remain significant in the 
model for COPD nor Control subjects. 
 
5.2.5:  ATR1 A1166C polymorphism 
 
Characteristics of COPD and Control groups according to ATR1 genotype are shown 
in Tables 5.6 and 5.7.  No significant difference was seen between genotype groups 
for any parameters studied in either COPD or control groups. 
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Table 5.6:  Characteristics of COPD subjects according to ATR1 genotype 
 AA 
(n=53) 
AC 
(n=40) 
CC 
(n=6) 
  
Age, yr 64.3 (7.9) 65.0 (10.3) 63.8 (10.5)   
FFM, kg
 
43.1 (7.5) 44.7 (10.0) 50.4 (4.5)   
QMVC, kg
 
27.6 (11.3) 29.2 (13.9) 38.7 (7.7)   
FEV1, % pred 39.3 (19.7) 46.7 (21.9) 49 (24.2)   
25(OH)D, nmol/l 48.2 (28.7) 50.3 (23.5) 42.5 (15.7)   
 
Table 5.7:  Characteristics of Control Subjects according to ATR1 genotype 
 AA 
(n=48) 
AC 
(n=42) 
CC 
(n=7) 
  
Age, yr 64.6 (9.3) 62.7 (8.0) 57.9 (8.6)   
FFM, kg
 
50.7 (15.1) 52.8 (12.0) 58.8 (18.6)   
QMVC, kg
 
38.9 (15.0) 43.1 (12.0) 47.1 (13.3)   
FEV1, % pred 100.4 (17.8) 102.0 (14.8) 100.9 (13.9)   
25(OH)D, nmol/l 53.3 (31.7) 53.7 (21.6) 68.7 (38.4)   
 
When a univariate linear model was used to look for factors influencing muscle 
strength, ATR1 genotype was not found to be significant. 
 
5.2.6:  Influence of combined genotype on muscle strength 
 
When all 3 genes were included in the univariate linear model looking at factors 
influencing QMVC in the COPD group, the following factors were found to be 
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significant: Age (F=9.6, p=0.003); FFM (F=9.4, p=0.003); ATR1 (F=5.9, p=0.001); 
ACE and AGT (F=5.1, p=0.001); ATR1 and AGT (F=12.0, p<0.001). 
 
In the control group, the following factors were significant: age (F=4.1, p=0.048); 
FFM (F=15.1, p<0.001).  ACE, ATR1 and AGT combined gave an F value of 2.39, 
p=0.059. 
 
5.2.7:  DBP rs7041 SNP 
 
Allele frequencies were similar in both COPD (MAF 0.41) and Control (MAF 0.42) 
groups and were similar to those reported in the NCBI SNP database (0.39). 
 
In the COPD group, a significant difference was found between genotype groups for 
FEV1 (% predicted) with the highest FEV1 in those homozygous for the T allele 
(51.3% ± 22.3) and the lowest in those who were homozygote ie GT (37.1% ± 16.6) 
(table 5.8 and figure 5.3).  . 
 
In the Control group, no significant difference was seen between genotype groups for 
any characteristics measured (table 5.9).  
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Table 5.8:  Characteristics of COPD group according to DBP rs7041 phenotype 
 GG 
(n=42) 
GT 
(n=35) 
TT 
(n=23) 
 
Age, yr 63.6 (8.5) 67.0 (8.9) 63.0 (9.7)  
BMI, kg/m
2
 24.0 (4.3) 23.6 (4.2) 24.7 (4.8)  
FFM, kg
 
44.5 (9.1) 43.2 (7.6) 45.6 (9.6)  
FEV1 % predicted
*
 42.4 (22.3) 37.1 (16.6) 51.3 (22.3) F=3.4, p=0.04 
5(OH)D, nmol/l 51.9 (28.7) 52.1 (26.7) 39.1 (15.1)  
1,25(OH)2D, pmol/l 87.6 (32.1) 82.2 (32.2) 70.0 (31.7)  
QMVC, kg
 
28.2 (12.0) 27.7 (11.8) 30.9 (13.6)  
 
Table 5.9:  Characteristics of Control Group according to DBP rs7041 
phenotype 
 
 GG 
(n=33) 
GT 
(n=45) 
TT 
(n=17) 
Age, yr 63.7 (8.2) 63.0 (8.3) 63.4 (11.2) 
BMI, kg/m
2
 27.1 (5.0) 25.6 (4.7) 24.9 (4.1) 
FFM, kg
 
56.2 (13.3) 50.8 (14.4) 48.5 (13.5) 
FEV1 % predicted 99.8 (16.1) 101.1 (17.0) 103.0 (13.0) 
25(OH)D, nmol/l 56.5 (28.8) 55.0 (30.2) 51.4 (26.5) 
1,25(OH)2D, pmol/l 79.8 (32.7) 83.2 (32.7) 83.3 (18.6) 
QMVC, kg
 
44.9 (14.0) 41.5 (14.3) 35.1 (9.0) 
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Figure 5.3:  FEV1 (% predicted) according to DBP rs 7041 phenotype in COPD 
and Control Groups 
 
 
: 
5.2.8:  DBP rs4588 SNP 
 
Allele frequencies were similar in both COPD (MAF 0.26) and Control (MAF 0.30) 
groups and were similar to those reported in the NCBI SNP database (0.22). 
 
In the COPD group, a significant difference was seen between genotypes for 
FFM(kg): CC 44.2 ± 8.6; CA 42.4 ± 8.2; AA 52.3 ± 7.3, F=5.0, p=0.009, QMVC 
(kg): CC 28.3 ± 12.4; CA 26.5 ± 10.8; AA  39.1 ± 12.8, F=4.3, p=0.02, and Handgrip 
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(kg): CC 31.3 ± 11.3); CA 32.7 ± 9.4; AA 41.7 ± 12.0, F=3.6, p=0.03 (figure 5.4).  
When QMVC and handgrip were corrected for FFM, there was no significant 
difference found (table 5.10). 
 
Table 5.10:  Characteristics of COPD Group according to DBP rs4588 
phenotype 
 
 CC 
(n=59) 
CA 
(n=32) 
AA 
(n=10) 
  
Age, yr 64.1 (8.5) 65.7 (10.3) 64.7 (7.9)   
BMI, kg/m
2* 
24.1 (4.2) 22.9 (4.2) 27.0 (4.6) F=3.6 p=0.03 
FFM, kg
* 
44.2 (8.6) 42.4 (8.2) 52.3 (7.3) F=5.0 p=0.009 
FEV1 % predicted 41.3 (22.5) 42.2 (17.3) 53.0 (20.9)   
25(OH)D, nmol/l 50.8 (27.8) 46.2 (25.2) 44.8 (13.3)   
QMVC, kg
* 
28.3 (12.4) 26.5 (10.8) 39.1 (12.8) F=4.3 p=0.02 
handgrip, kg
* 
31.3 (11.3) 32.7 (9.4) 41.7 (12.0) F=3.6 p=0.03 
SNiP, cmH20 63.3 (17.5) 62.0 (21.7) 72.6 (32.1)   
QMVC / FFM 0.6 (0.2) 0.6 (0.2) 0.8 (0.2)   
handgrip / FFM 0.7 (0.2) 0.8 (0.2) 0.8 (0.2)   
 
In the control group, a significant difference was found only for SNiP between 
genotypes as follows CC 87.7 ± 23.5; CA 76.1 ± 21.2; AA 63.9 ± 29.2, F=4.5, p=0.01 
(table 5.11). 
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Table 5.11:  Characteristics of Control Group according to DBP rs4588 
phenotype 
 CC 
(n=47) 
CA 
(n=42) 
AA 
(n=8) 
  
Age, yr 62.9 (8.5) 64.3 (9.5) 59.6 (6.9)   
BMI, kg/m
2
 26.4 (4.5) 25.6 (5.0) 24.2 (2.7)   
FFM, kg
 
54.9 (13.7) 49.8 (14.2) 46.7 (12.8)   
FEV1 % predicted 100.2 (15.8) 103.1 (17.2) 98.9 (14.6)   
25(OH)D, nmol/l 60.6 (31.8) 50.8 (25.5) 42.2 (15.2)   
QMVC, kg
 
44.4 (15.4) 39.6 (12.6) 34.7 (7.3)   
Handgrip, kg 38.3 (10.7) 35.6 (11.4) 32.1 (5.1)   
SNiP, cmH20
*
 87.7 (23.5) 76.1 (21.2) 63.9 (29.2) F=4.5 p=0.01 
QMVC / FFM 0.8 (0.2) 0.8 (0.2) 0.8 (0.2)   
Handgrip / FFM 0.7 (0.1)  0.7 (0.1) 0.7 (0.1)   
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Figure 5.4:  FFM according to rs4588 genotype for COPD and Control Groups 
 
 
 
 
5.3:  Discussion 
 
The significant findings of this genotyping study in a predominantly Caucasian COPD 
population, and age and sex matched healthy elderly control group are as follows: 
 
1) The ACE I/D polymorphism, the ATR1 A1166C polymorphism and the 
AGT Met235Thr polymorphism have a combined influence on skeletal 
muscle strength in the COPD group. 
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2) The ACE I/D polymorphism is associated with serum 25(OH)D 
concentration in a healthy elderly population 
3) The D allele of the ACE I/D polymorphism and the T allele of the AGT 
Met235Thr polymorphism have a higher frequency in the COPD group 
compared to the control group. 
4) The AA genotype of the rs4588 DBP polymorphism is associated with 
higher FFM and measures of muscle strength in the COPD group. 
 
The main finding of this study shows that genetic polymorphisms which influence the 
renin-angiotensin system have a combined influence on skeletal muscle function in 
COPD subjects.  Polymorphisms which have evidence of increased RAS activity are 
associated with increased QMVC in these subjects contributing to the growing 
evidence that the RAS has effects on skeletal muscle. 
 
The surprising finding was the relationship between the ACE I/D polymorphism and 
serum 25(OH)D concentration which remained significant when corrected for other 
confounding variables.  A relationship between 1,25(OH)2D and the renin-angiotensin 
system has been previously documented.  1,25(OH)2D has been shown to have an 
inverse relationship with blood pressure (Kristal-Boneh, Froom et al. 1997) and 
plasma renin (Burgess, Hawkins et al. 1990).  VDR KO mice have been shown to 
have increased renin expression and plasma angiotensin II production, with 
subsequent hypertension, cardiac hypertrophy and increased water intake (Li, Kong et 
al. 2002).  However the mechanism of action of 1,25(OH)2D on the renin angiotensin 
system is not clear and recent studies with VDR agonists have not shown effects on 
the RAS (Bernini, Carrara et al.; Atchison, Harding et al.). 
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The findings of astronger measures of skeletal muscle strength with the rs 4588 DBP 
polymorphism are likely to be related to an influence on FFM.  This may have been a 
chance finding, but when an interaction analysis was performed, a combined effect of 
COPD and the rs4588 polymorphism was significant (F=3.41, p=0.35).  It would 
therefore appear that in COPD subjects, the AA genotype of the rs4588 DBP 
polymorphism indirectly confers and increase in skeletal muscle strength through an 
increase in FFM.  These effects are unrelated to serum 25(OH)D concentrations. 
 
The findings in this study may have been through chance but the effects of the ACE 
genotype on serum 25(OH)D concentration was very significant and became more so 
when corrected for confounding factors (p<0.001).  Serum 25(OH)D concentration 
increased with the DD genotype which has been related to power performance in 
sport and it is possible that this effect on muscle performance is mediated through 
25(OH)D which has been shown to effect type II muscle fibres in humans.  The II 
genotype being related to proportion of Type I fibres in skeletal muscle and endurance 
performance in sport is also consistent with the lower 25(OH)D levels found in this 
group.  Taking into account the findings of the muscle biopsy sub study, we can 
postulate that the vitamin D pathway has an important role in controlling muscle fibre 
type. 
 
COPD patients are an example of the opposite end of the spectrum of environmental 
influences on skeletal muscle to elite athletes and this perhaps explains why the 
genetic influences on muscle function are more pronounced.  In both circumstances 
skeletal muscle is forced to function under more extreme conditions and genetic 
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influences may be more exaggerated. This could explain why no relationship between 
genotype and muscle function was found in the control group in this study, and in the 
study by Hopkinson et al.  This does not explain the increased D allele frequency seen 
in the COPD group in our study which may be a chance finding.  A recent meta-
analysis of studies looking at allele frequencies of the ACE I/D polymorphism found 
only a significant increased risk of COPD with the D allele in Asian populations (Li, 
Lan et al.).  COPD subjects with quadriceps weakness have bee shown to have an 
increased mortality (Swallow, Reyes et al. 2007) and it is therefore possible that the D 
allele confers a survival benefit in COPD through its influence on muscle strength. 
 
The potential for multiple comparisons is a limitation of this study.  However the 
genes studied were carefully selected for their known or potential effect on skeletal 
muscle or the renin-angiotensin system.  A p value of <0.01 was considered 
significant.  Another limitation is the inclusion of a small number of non-Caucasian 
subjects.  However the numbers of these were small and when excluded from the 
analysis, no difference in results was seen. 
 
In summary, this study shows a combined influence of genes in the renin-angiotensin 
pathway on skeletal muscle function in COPD subjects, as well as further evidence for 
a link between the Vitamin D pathway and the renin-angiotensin system.  Effects of 
the DBP rs4588 polymorphism on FFM in COPD subjects have also been 
demonstrated.  Further studies to investigate the role of the RAS in skeletal muscle 
and its interaction with 25(OH)D and 1,25(OH)2D are required. 
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Chapter 6:  Conclusions 
 
This work aimed to try and unravel some of the actions of a pleiotropic hormone on 
an adaptable organ in a multisystem disease.  It has been to a small extent successful 
in adding some knowledge to the field but a large amount of work remains to be done 
in order to unravel the complexities involved. 
 
The clinical chapter threw up the initial surprising finding that there was no apparent 
relationship between serum 25(OH)D concentration and skeletal muscle function in 
COPD patients.   This raises the possibility of resistance to 1,25(OH)2D  in skeletal 
muscle which is supported by the findings of the muscle biopsy study where strong 
associations in the healthy elderly control groups were not replicated in the COPD 
group, suggesting that a failure of communication may occur.  Subsequent studies 
looking at vitamin D supplementation in COPD have failed to find an improvement in 
muscle function which adds weight to this argument. 
 
The influences of genetic polymorphisms in the ACE pathway appear to be more 
profound in COPD where the muscle is subjected to an ‘extreme’ environment.  These 
results contribute to the emerging evidence that the renin-angiotensin system is 
involved in skeletal muscle function and in fact appears to be linked to the Vitamin D 
pathway. 
 
Further research leading on from this work would focus on the role of 1,25(OH)2D 
and fibre type in skeletal muscle, the presence or absence of the VDR in the skeletal 
muscle of COPD subjects and the potential link between the RAS and Vitamin D in 
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skeletal muscle.  A trial of VDR agonists in COPD subjects may also go some way 
towards relieving the burden of this chronic debilitating disease if found to be of 
benefit. 
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